US20060094722A1 - Combination drug - Google Patents
Combination drug Download PDFInfo
- Publication number
- US20060094722A1 US20060094722A1 US10/528,353 US52835303A US2006094722A1 US 20060094722 A1 US20060094722 A1 US 20060094722A1 US 52835303 A US52835303 A US 52835303A US 2006094722 A1 US2006094722 A1 US 2006094722A1
- Authority
- US
- United States
- Prior art keywords
- group
- butynyl
- methyl
- compound
- piperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940000425 combination drug Drugs 0.000 title description 2
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract description 86
- 102100040918 Pro-glucagon Human genes 0.000 claims abstract description 85
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims abstract description 67
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 66
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims abstract description 58
- 230000000694 effects Effects 0.000 claims abstract description 34
- 229940123208 Biguanide Drugs 0.000 claims abstract description 30
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims abstract description 30
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 687
- -1 3-amino-piperidin-1-yl group Chemical group 0.000 claims description 145
- 125000001424 substituent group Chemical group 0.000 claims description 88
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 67
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 42
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 37
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims description 28
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 27
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims description 27
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 25
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 24
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 23
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 230000002708 enhancing effect Effects 0.000 claims description 16
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims description 15
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims description 15
- 125000006719 (C6-C10) aryl (C1-C6) alkyl group Chemical group 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 13
- 230000003449 preventive effect Effects 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 12
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 12
- 229960003105 metformin Drugs 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 claims description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000004434 sulfur atom Chemical group 0.000 claims description 7
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 6
- WMSQDGWQPKIRTA-UHFFFAOYSA-N 3-but-2-ynyl-5-methyl-2-piperazin-1-ylimidazo[4,5-d]pyridazin-4-one Chemical compound N=1C=2C=NN(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 WMSQDGWQPKIRTA-UHFFFAOYSA-N 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 5
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 125000002619 bicyclic group Chemical group 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- HALCIKPRHJJAHE-UHFFFAOYSA-N 2-(7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)oxybenzamide Chemical compound CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1OC1=CC=CC=C1C(N)=O HALCIKPRHJJAHE-UHFFFAOYSA-N 0.000 claims description 4
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 4
- JUSIGURQRFKQKK-UHFFFAOYSA-N 7-but-2-ynyl-1,3-dimethyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 JUSIGURQRFKQKK-UHFFFAOYSA-N 0.000 claims description 4
- IECPBQGZEFHLLH-UHFFFAOYSA-N 7-but-2-ynyl-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CC#CC)C=1N1CCNCC1 IECPBQGZEFHLLH-UHFFFAOYSA-N 0.000 claims description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- ISFNRMCOOOQFSV-UHFFFAOYSA-N 1,7-bis(but-2-ynyl)-3-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)N(CC#CC)C(=O)C=2N(CC#CC)C=1N1CCNCC1 ISFNRMCOOOQFSV-UHFFFAOYSA-N 0.000 claims description 3
- RCTSOUGGJFRGSX-UHFFFAOYSA-N 2-(7-but-2-ynyl-3-methyl-2,6-dioxo-8-piperazin-1-ylpurin-1-yl)acetonitrile Chemical compound N=1C=2N(C)C(=O)N(CC#N)C(=O)C=2N(CC#CC)C=1N1CCNCC1 RCTSOUGGJFRGSX-UHFFFAOYSA-N 0.000 claims description 3
- ZWWUPVXCCWUAAC-UHFFFAOYSA-N 2-[7-but-2-ynyl-2,6-dioxo-1-(2-phenylethyl)-8-piperazin-1-ylpurin-3-yl]-n-methylacetamide Chemical compound CC#CCN1C=2C(=O)N(CCC=3C=CC=CC=3)C(=O)N(CC(=O)NC)C=2N=C1N1CCNCC1 ZWWUPVXCCWUAAC-UHFFFAOYSA-N 0.000 claims description 3
- CURKIBSWOALNNF-UHFFFAOYSA-N 2-[7-but-2-ynyl-2,6-dioxo-1-(2-phenylethyl)-8-piperazin-1-ylpurin-3-yl]acetic acid Chemical compound O=C1C=2N(CC#CC)C(N3CCNCC3)=NC=2N(CC(O)=O)C(=O)N1CCC1=CC=CC=C1 CURKIBSWOALNNF-UHFFFAOYSA-N 0.000 claims description 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 3
- HYCVOQLTFYNPRK-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-3-(2-oxopyrrolidin-3-yl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N1C1CCNC1=O HYCVOQLTFYNPRK-UHFFFAOYSA-N 0.000 claims description 3
- IMGVFBZJGFJHRR-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-3-(oxolan-2-ylmethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N1CC1CCCO1 IMGVFBZJGFJHRR-UHFFFAOYSA-N 0.000 claims description 3
- VXPDXZIAPQBACQ-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-3-phenacyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N1CC(=O)C1=CC=CC=C1 VXPDXZIAPQBACQ-UHFFFAOYSA-N 0.000 claims description 3
- DMVIQDKOTMDZSW-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurine-2-carbonitrile Chemical compound N=1C=2N=C(C#N)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 DMVIQDKOTMDZSW-UHFFFAOYSA-N 0.000 claims description 3
- ARGDHXCKQCQRIS-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-8-piperazin-1-yl-3-propan-2-ylpurine-2,6-dione Chemical compound N=1C=2N(C(C)C)C(=O)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 ARGDHXCKQCQRIS-UHFFFAOYSA-N 0.000 claims description 3
- DSRLMMVLRZQNEC-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-8-piperazin-1-yl-3-propylpurine-2,6-dione Chemical compound CC#CCN1C=2C(=O)N(C)C(=O)N(CCC)C=2N=C1N1CCNCC1 DSRLMMVLRZQNEC-UHFFFAOYSA-N 0.000 claims description 3
- GSSPOWZDYWXDHX-UHFFFAOYSA-N 7-but-2-ynyl-3-(2-ethoxyethyl)-1-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound CC#CCN1C=2C(=O)N(C)C(=O)N(CCOCC)C=2N=C1N1CCNCC1 GSSPOWZDYWXDHX-UHFFFAOYSA-N 0.000 claims description 3
- VORUDDWGNZTCEE-UHFFFAOYSA-N 7-but-2-ynyl-3-(2-ethoxyethyl)-1-phenacyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound CC#CCN1C=2C(=O)N(CC(=O)C=3C=CC=CC=3)C(=O)N(CCOCC)C=2N=C1N1CCNCC1 VORUDDWGNZTCEE-UHFFFAOYSA-N 0.000 claims description 3
- UBGNSNGNZCTVHC-UHFFFAOYSA-N 7-but-2-ynyl-3-(2-oxo-2-pyrrolidin-1-ylethyl)-1-(2-phenylethyl)-8-piperazin-1-ylpurine-2,6-dione Chemical compound O=C1N(CCC=2C=CC=CC=2)C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N1CC(=O)N1CCCC1 UBGNSNGNZCTVHC-UHFFFAOYSA-N 0.000 claims description 3
- TWGVYFLEJNMERE-UHFFFAOYSA-N 7-but-2-ynyl-3-(3,3-dimethyl-2-oxobutyl)-1-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound N=1C=2N(CC(=O)C(C)(C)C)C(=O)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 TWGVYFLEJNMERE-UHFFFAOYSA-N 0.000 claims description 3
- HBNMKEWNEFCISI-UHFFFAOYSA-N 7-but-2-ynyl-3-ethyl-1-methyl-8-piperazin-1-ylpurine-2,6-dione Chemical compound CC#CCN1C=2C(=O)N(C)C(=O)N(CC)C=2N=C1N1CCNCC1 HBNMKEWNEFCISI-UHFFFAOYSA-N 0.000 claims description 3
- 125000002946 cyanobenzyl group Chemical group 0.000 claims description 3
- QGVFJAVEJVFFMZ-UHFFFAOYSA-N ethyl 2-(7-but-2-ynyl-1-methyl-2,6-dioxo-8-piperazin-1-ylpurin-3-yl)propanoate Chemical compound CC#CCN1C=2C(=O)N(C)C(=O)N(C(C)C(=O)OCC)C=2N=C1N1CCNCC1 QGVFJAVEJVFFMZ-UHFFFAOYSA-N 0.000 claims description 3
- LVTUZHKMECPWML-UHFFFAOYSA-N ethyl 2-[7-but-2-ynyl-2,6-dioxo-1-(2-phenylethyl)-8-piperazin-1-ylpurin-3-yl]acetate Chemical compound CC#CCN1C=2C(=O)N(CCC=3C=CC=CC=3)C(=O)N(CC(=O)OCC)C=2N=C1N1CCNCC1 LVTUZHKMECPWML-UHFFFAOYSA-N 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- PFOTUCWQFULBPZ-UHFFFAOYSA-N methyl 2-(7-but-2-ynyl-1-methyl-2,6-dioxo-8-piperazin-1-ylpurin-3-yl)-2-phenylacetate Chemical compound C1=2N=C(N3CCNCC3)N(CC#CC)C=2C(=O)N(C)C(=O)N1C(C(=O)OC)C1=CC=CC=C1 PFOTUCWQFULBPZ-UHFFFAOYSA-N 0.000 claims description 3
- HJSMGFUCIQTHGW-UHFFFAOYSA-N methyl 2-(7-but-2-ynyl-1-methyl-2,6-dioxo-8-piperazin-1-ylpurin-3-yl)acetate Chemical compound CC#CCN1C=2C(=O)N(C)C(=O)N(CC(=O)OC)C=2N=C1N1CCNCC1 HJSMGFUCIQTHGW-UHFFFAOYSA-N 0.000 claims description 3
- GJQOKGRZJIIDFA-UHFFFAOYSA-N methyl 2-(7-but-2-ynyl-2,6-dioxo-1-phenacyl-8-piperazin-1-ylpurin-3-yl)acetate Chemical compound CC#CCN1C=2C(=O)N(CC(=O)C=3C=CC=CC=3)C(=O)N(CC(=O)OC)C=2N=C1N1CCNCC1 GJQOKGRZJIIDFA-UHFFFAOYSA-N 0.000 claims description 3
- XCLZZVZJLPEGSB-UHFFFAOYSA-N methyl 2-(7-but-2-ynyl-3-methyl-2,6-dioxo-8-piperazin-1-ylpurin-1-yl)acetate Chemical compound CC#CCN1C=2C(=O)N(CC(=O)OC)C(=O)N(C)C=2N=C1N1CCNCC1 XCLZZVZJLPEGSB-UHFFFAOYSA-N 0.000 claims description 3
- 125000006504 o-cyanobenzyl group Chemical group [H]C1=C([H])C(C#N)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- BKVALOSDPLKKRR-UHFFFAOYSA-N 2-(3-aminopiperidin-1-yl)-3-but-2-ynyl-5-methylimidazo[4,5-d]pyridazin-4-one Chemical compound N=1C=2C=NN(C)C(=O)C=2N(CC#CC)C=1N1CCCC(N)C1 BKVALOSDPLKKRR-UHFFFAOYSA-N 0.000 claims description 2
- HMFYVRLLPZSBFN-UHFFFAOYSA-N 2-[(3-but-2-ynyl-4-oxo-2-piperazin-1-ylimidazo[4,5-d]pyridazin-5-yl)methyl]benzonitrile Chemical compound O=C1C=2N(CC#CC)C(N3CCNCC3)=NC=2C=NN1CC1=CC=CC=C1C#N HMFYVRLLPZSBFN-UHFFFAOYSA-N 0.000 claims description 2
- WHCVAYNAPFMUGY-UHFFFAOYSA-N 2-[7-but-2-ynyl-2,6-dioxo-1-(2-phenylethyl)-8-piperazin-1-ylpurin-3-yl]-n-phenylacetamide Chemical compound O=C1N(CCC=2C=CC=CC=2)C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N1CC(=O)NC1=CC=CC=C1 WHCVAYNAPFMUGY-UHFFFAOYSA-N 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- OPSYBASGLOSUDU-UHFFFAOYSA-N 7-but-2-ynyl-1-[(2-cyanophenyl)methyl]-6-oxo-8-piperazin-1-ylpurine-2-carbonitrile Chemical compound O=C1C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C(C#N)N1CC1=CC=CC=C1C#N OPSYBASGLOSUDU-UHFFFAOYSA-N 0.000 claims description 2
- HVPZZMJBPNNWNY-UHFFFAOYSA-N 7-but-2-ynyl-3-methyl-8-piperazin-1-yl-1-prop-2-ynylpurine-2,6-dione Chemical compound N=1C=2N(C)C(=O)N(CC#C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 HVPZZMJBPNNWNY-UHFFFAOYSA-N 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
- 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 claims description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract description 30
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract description 30
- 239000003112 inhibitor Substances 0.000 abstract description 24
- 238000006243 chemical reaction Methods 0.000 description 323
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 315
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 231
- 239000000203 mixture Substances 0.000 description 227
- 239000000243 solution Substances 0.000 description 226
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 183
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 173
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 165
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 156
- 238000004519 manufacturing process Methods 0.000 description 150
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 117
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 116
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 114
- 239000002904 solvent Substances 0.000 description 114
- 238000005160 1H NMR spectroscopy Methods 0.000 description 105
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 102
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 94
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 93
- 239000012044 organic layer Substances 0.000 description 87
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 84
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 84
- 239000002585 base Substances 0.000 description 76
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 75
- 230000002829 reductive effect Effects 0.000 description 69
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 67
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 54
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 51
- 229910000027 potassium carbonate Inorganic materials 0.000 description 47
- 235000011181 potassium carbonates Nutrition 0.000 description 47
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 46
- 238000010898 silica gel chromatography Methods 0.000 description 46
- 239000003153 chemical reaction reagent Substances 0.000 description 43
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 39
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 39
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 36
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 36
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 34
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 30
- 238000006467 substitution reaction Methods 0.000 description 30
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 29
- 239000011541 reaction mixture Substances 0.000 description 29
- 238000010511 deprotection reaction Methods 0.000 description 28
- 235000011121 sodium hydroxide Nutrition 0.000 description 28
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 24
- 239000003054 catalyst Substances 0.000 description 24
- 238000004007 reversed phase HPLC Methods 0.000 description 24
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 22
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 22
- 239000012312 sodium hydride Substances 0.000 description 22
- 229910000104 sodium hydride Inorganic materials 0.000 description 22
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 20
- 239000007864 aqueous solution Substances 0.000 description 20
- 238000001914 filtration Methods 0.000 description 20
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 19
- 239000000706 filtrate Substances 0.000 description 19
- 125000006239 protecting group Chemical group 0.000 description 19
- 125000003277 amino group Chemical group 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 16
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 16
- 229910052751 metal Inorganic materials 0.000 description 15
- 239000002184 metal Substances 0.000 description 15
- DRJQXHGMGWUQBT-UHFFFAOYSA-N tert-butyl 4-(7-but-2-ynyl-2-chloro-1-methyl-6-oxopurin-8-yl)piperazine-1-carboxylate Chemical compound N=1C=2N=C(Cl)N(C)C(=O)C=2N(CC#CC)C=1N1CCN(C(=O)OC(C)(C)C)CC1 DRJQXHGMGWUQBT-UHFFFAOYSA-N 0.000 description 15
- LNNXOEHOXSYWLD-UHFFFAOYSA-N 1-bromobut-2-yne Chemical compound CC#CCBr LNNXOEHOXSYWLD-UHFFFAOYSA-N 0.000 description 14
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 14
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 14
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 14
- 239000012299 nitrogen atmosphere Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 239000003638 chemical reducing agent Substances 0.000 description 13
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 12
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 238000011010 flushing procedure Methods 0.000 description 12
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 12
- 235000019341 magnesium sulphate Nutrition 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 229910001873 dinitrogen Inorganic materials 0.000 description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 10
- 229910000024 caesium carbonate Inorganic materials 0.000 description 10
- 230000002140 halogenating effect Effects 0.000 description 10
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 10
- 229910052808 lithium carbonate Inorganic materials 0.000 description 10
- 239000012046 mixed solvent Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 239000012279 sodium borohydride Substances 0.000 description 9
- 229910000033 sodium borohydride Inorganic materials 0.000 description 9
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 8
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 8
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 8
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 8
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- 235000019270 ammonium chloride Nutrition 0.000 description 7
- 239000012298 atmosphere Substances 0.000 description 7
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 7
- 238000005660 chlorination reaction Methods 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229910000103 lithium hydride Inorganic materials 0.000 description 7
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 7
- 239000007800 oxidant agent Substances 0.000 description 7
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 7
- 229910000105 potassium hydride Inorganic materials 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- GMSNIKWWOQHZGF-UHFFFAOYSA-N 3-methyl-9H-xanthine Chemical compound O=C1NC(=O)N(C)C2=C1N=CN2 GMSNIKWWOQHZGF-UHFFFAOYSA-N 0.000 description 6
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- WIYVXOVNPSWAHX-UHFFFAOYSA-N tert-butyl 4-(3-but-2-ynyl-5-methyl-4-oxoimidazo[4,5-d]pyridazin-2-yl)piperazine-1-carboxylate Chemical compound N=1C=2C=NN(C)C(=O)C=2N(CC#CC)C=1N1CCN(C(=O)OC(C)(C)C)CC1 WIYVXOVNPSWAHX-UHFFFAOYSA-N 0.000 description 6
- KQASZIGYCGCQDX-UHFFFAOYSA-N tert-butyl 4-(7-but-2-ynyl-2,6-dichloropurin-8-yl)piperazine-1-carboxylate Chemical compound N=1C2=NC(Cl)=NC(Cl)=C2N(CC#CC)C=1N1CCN(C(=O)OC(C)(C)C)CC1 KQASZIGYCGCQDX-UHFFFAOYSA-N 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000007868 Raney catalyst Substances 0.000 description 5
- 229910000564 Raney nickel Inorganic materials 0.000 description 5
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 5
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 229960004979 fampridine Drugs 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 238000005658 halogenation reaction Methods 0.000 description 5
- 230000001035 methylating effect Effects 0.000 description 5
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 229960000581 salicylamide Drugs 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- NEGZVXFDJSNCKD-UHFFFAOYSA-N tert-butyl 4-(1-but-2-ynyl-7-oxo-6h-imidazo[4,5-d]pyridazin-2-yl)piperazine-1-carboxylate Chemical compound N=1C=2C=NNC(=O)C=2N(CC#CC)C=1N1CCN(C(=O)OC(C)(C)C)CC1 NEGZVXFDJSNCKD-UHFFFAOYSA-N 0.000 description 5
- VVWARAROKUOPQX-UHFFFAOYSA-N tert-butyl 4-(7-but-2-ynyl-2-chloro-6-oxo-3h-purin-8-yl)piperazine-1-carboxylate Chemical compound N=1C=2N=C(Cl)NC(=O)C=2N(CC#CC)C=1N1CCN(C(=O)OC(C)(C)C)CC1 VVWARAROKUOPQX-UHFFFAOYSA-N 0.000 description 5
- WUOQXNWMYLFAHT-UHFFFAOYSA-N tert-butyl n-piperidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCCNC1 WUOQXNWMYLFAHT-UHFFFAOYSA-N 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 4
- WMPWSWMSTJAAPF-UHFFFAOYSA-N 2-bromo-1h-imidazole-4,5-dicarbonitrile Chemical compound BrC1=NC(C#N)=C(C#N)N1 WMPWSWMSTJAAPF-UHFFFAOYSA-N 0.000 description 4
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 4
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 4
- CPLWLMDNRLTZHK-UHFFFAOYSA-N 7-but-2-ynyl-3-methylpurine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2CC#CC CPLWLMDNRLTZHK-UHFFFAOYSA-N 0.000 description 4
- SJEXZCRZWVWXPY-UHFFFAOYSA-N 7-but-2-ynyl-8-chloro-3-methylpurine-2,6-dione Chemical compound CN1C(=O)NC(=O)C2=C1N=C(Cl)N2CC#CC SJEXZCRZWVWXPY-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- 150000001350 alkyl halides Chemical class 0.000 description 4
- 238000007112 amidation reaction Methods 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 4
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 4
- ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical compound CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- MKIJJIMOAABWGF-UHFFFAOYSA-N methyl 2-sulfanylacetate Chemical compound COC(=O)CS MKIJJIMOAABWGF-UHFFFAOYSA-N 0.000 description 4
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229910003446 platinum oxide Inorganic materials 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- UGUMKZDZJGZAFS-UHFFFAOYSA-N tert-butyl 4-(3-but-2-ynyl-4-oxo-5h-imidazo[4,5-c]pyridin-2-yl)piperazine-1-carboxylate Chemical compound N=1C=2C=CNC(=O)C=2N(CC#CC)C=1N1CCN(C(=O)OC(C)(C)C)CC1 UGUMKZDZJGZAFS-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- USQCVQKTAQCGHR-UHFFFAOYSA-N (1-methyl-2,6-dioxo-7h-purin-3-yl)methyl 2,2-dimethylpropanoate Chemical compound O=C1N(C)C(=O)N(COC(=O)C(C)(C)C)C2=C1NC=N2 USQCVQKTAQCGHR-UHFFFAOYSA-N 0.000 description 3
- ZSOPWZQRZHWYFY-NUXPJIRBSA-N (2s,3s)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.CC[C@H](C)[C@H](N)C(=O)N1CCSC1 ZSOPWZQRZHWYFY-NUXPJIRBSA-N 0.000 description 3
- IMCMJLZQYAUSFW-IUCAKERBSA-N (2s,3s)-2-amino-3-methyl-1-pyrrolidin-1-ylpentan-1-one Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCCC1 IMCMJLZQYAUSFW-IUCAKERBSA-N 0.000 description 3
- LRSDKIVOTHPPBI-UHFFFAOYSA-N (7-benzyl-2,6-dioxopurin-3-yl)methyl 2,2-dimethylpropanoate Chemical compound C1=2C(=O)NC(=O)N(COC(=O)C(C)(C)C)C=2N=CN1CC1=CC=CC=C1 LRSDKIVOTHPPBI-UHFFFAOYSA-N 0.000 description 3
- SSUJUUNLZQVZMO-UHFFFAOYSA-N 1,2,3,4,8,9,10,10a-octahydropyrimido[1,2-a]azepine Chemical compound C1CCC=CN2CCCNC21 SSUJUUNLZQVZMO-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- SKOBTCPKYOGFAZ-UHFFFAOYSA-N 1-benzyl-2-piperazin-1-yl-6h-imidazo[4,5-d]pyridazin-7-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)NN=CC=2N=C1N1CCNCC1 SKOBTCPKYOGFAZ-UHFFFAOYSA-N 0.000 description 3
- LOYZVRIHVZEDMW-UHFFFAOYSA-N 1-bromo-3-methylbut-2-ene Chemical compound CC(C)=CCBr LOYZVRIHVZEDMW-UHFFFAOYSA-N 0.000 description 3
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 3
- QGXNHCXKWFNKCG-UHFFFAOYSA-N 2-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC=C1C#N QGXNHCXKWFNKCG-UHFFFAOYSA-N 0.000 description 3
- IHBAVXVTGLANPI-QMMMGPOBSA-N 2-amino-3-methyl-1-pyrrolidin-1-yl-butan-1-one Chemical compound CC(C)[C@H](N)C(=O)N1CCCC1 IHBAVXVTGLANPI-QMMMGPOBSA-N 0.000 description 3
- JSTSAENIJBLKIN-UHFFFAOYSA-N 2-chloro-5-methyl-1-tritylimidazo[4,5-d]pyridazin-4-one Chemical compound ClC1=NC=2C(=O)N(C)N=CC=2N1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 JSTSAENIJBLKIN-UHFFFAOYSA-N 0.000 description 3
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 3
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- QKDLSMIQHOUFQB-UHFFFAOYSA-N 3-but-2-ynyl-2-piperazin-1-yl-5h-imidazo[4,5-c]pyridin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2C=CNC(=O)C=2N(CC#CC)C=1N1CCNCC1 QKDLSMIQHOUFQB-UHFFFAOYSA-N 0.000 description 3
- NGBXNLJJRVHTOI-UEWDXFNNSA-N 6-[[3-amino-4-[(2s)-2-cyanopyrrolidin-1-yl]-4-oxobutyl]amino]pyridine-3-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)C(N)CCNC1=CC=C(C#N)C=N1 NGBXNLJJRVHTOI-UEWDXFNNSA-N 0.000 description 3
- GEJWNLQRMVMTIX-UHFFFAOYSA-N 7-but-2-ynyl-2,6,8-trichloropurine Chemical compound ClC1=NC(Cl)=C2N(CC#CC)C(Cl)=NC2=N1 GEJWNLQRMVMTIX-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 3
- 230000009435 amidation Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 3
- AMVCFIFDMKEIRE-UHFFFAOYSA-N methyl 2-(2-bromophenyl)acetate Chemical compound COC(=O)CC1=CC=CC=C1Br AMVCFIFDMKEIRE-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 3
- 125000002560 nitrile group Chemical group 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000006103 sulfonylation Effects 0.000 description 3
- 238000005694 sulfonylation reaction Methods 0.000 description 3
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- NCMMPXJACHUSFN-UHFFFAOYSA-N tert-butyl 4-(1-benzyl-7-oxo-6h-imidazo[4,5-d]pyridazin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)NN=C2 NCMMPXJACHUSFN-UHFFFAOYSA-N 0.000 description 3
- DXESPWLBISCQPL-UHFFFAOYSA-N tert-butyl 4-(7-but-2-ynyl-1-methyl-2,6-dioxo-3h-purin-8-yl)piperazine-1-carboxylate Chemical compound N=1C=2NC(=O)N(C)C(=O)C=2N(CC#CC)C=1N1CCN(C(=O)OC(C)(C)C)CC1 DXESPWLBISCQPL-UHFFFAOYSA-N 0.000 description 3
- LYNKOTMZYFSUCD-UHFFFAOYSA-N tert-butyl 4-(7-but-2-ynyl-3-methyl-2,6-dioxopurin-8-yl)piperazine-1-carboxylate Chemical compound N=1C=2N(C)C(=O)NC(=O)C=2N(CC#CC)C=1N1CCN(C(=O)OC(C)(C)C)CC1 LYNKOTMZYFSUCD-UHFFFAOYSA-N 0.000 description 3
- ATVMHORXTHTUGY-UHFFFAOYSA-N tert-butyl 4-[2,6-dichloro-7-(2-chlorophenyl)purin-8-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=NC2=NC(Cl)=NC(Cl)=C2N1C1=CC=CC=C1Cl ATVMHORXTHTUGY-UHFFFAOYSA-N 0.000 description 3
- JEVQOXPRVAIKLL-UHFFFAOYSA-N tert-butyl 4-[2-chloro-7-(2-chlorophenyl)-1-methyl-6-oxopurin-8-yl]piperazine-1-carboxylate Chemical compound C=1C=CC=C(Cl)C=1N1C=2C(=O)N(C)C(Cl)=NC=2N=C1N1CCN(C(=O)OC(C)(C)C)CC1 JEVQOXPRVAIKLL-UHFFFAOYSA-N 0.000 description 3
- ANOXWVYCKAJLFR-UHFFFAOYSA-N tert-butyl 4-[3-but-2-ynyl-4-oxo-5-(phenylmethoxymethyl)imidazo[4,5-d]pyridazin-2-yl]piperazine-1-carboxylate Chemical compound O=C1C=2N(CC#CC)C(N3CCN(CC3)C(=O)OC(C)(C)C)=NC=2C=NN1COCC1=CC=CC=C1 ANOXWVYCKAJLFR-UHFFFAOYSA-N 0.000 description 3
- VBIHDXXORWPUNV-UHFFFAOYSA-N tert-butyl 4-[4-oxo-5-(phenylmethoxymethyl)-1H-imidazo[4,5-d]pyridazin-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(N1)=NC2=C1C(=O)N(COCC=1C=CC=CC=1)N=C2 VBIHDXXORWPUNV-UHFFFAOYSA-N 0.000 description 3
- HEBSZPRRWBUABV-UHFFFAOYSA-N tert-butyl 4-[7-but-2-ynyl-2-(2-carbamoylphenoxy)-1-methyl-6-oxopurin-8-yl]piperazine-1-carboxylate Chemical compound CN1C(=O)C=2N(CC#CC)C(N3CCN(CC3)C(=O)OC(C)(C)C)=NC=2N=C1OC1=CC=CC=C1C(N)=O HEBSZPRRWBUABV-UHFFFAOYSA-N 0.000 description 3
- CADUDCPRQQWNSI-UHFFFAOYSA-N tert-butyl 4-[7-but-2-ynyl-2-chloro-1-[(2-cyanophenyl)methyl]-6-oxopurin-8-yl]piperazine-1-carboxylate Chemical compound O=C1C=2N(CC#CC)C(N3CCN(CC3)C(=O)OC(C)(C)C)=NC=2N=C(Cl)N1CC1=CC=CC=C1C#N CADUDCPRQQWNSI-UHFFFAOYSA-N 0.000 description 3
- CDCNRSYOAHQINO-UHFFFAOYSA-N tert-butyl n-[1-(7-but-2-ynyl-2-chloro-6-oxo-3h-purin-8-yl)piperidin-3-yl]carbamate Chemical compound N=1C=2N=C(Cl)NC(=O)C=2N(CC#CC)C=1N1CCCC(NC(=O)OC(C)(C)C)C1 CDCNRSYOAHQINO-UHFFFAOYSA-N 0.000 description 3
- IHLOTMVZLUVSHD-UHFFFAOYSA-N tert-butyl n-[1-[7-but-2-ynyl-2-chloro-1-[(2-cyanophenyl)methyl]-6-oxopurin-8-yl]piperidin-3-yl]carbamate Chemical compound O=C1C=2N(CC#CC)C(N3CC(CCC3)NC(=O)OC(C)(C)C)=NC=2N=C(Cl)N1CC1=CC=CC=C1C#N IHLOTMVZLUVSHD-UHFFFAOYSA-N 0.000 description 3
- 238000005980 thioamidation reaction Methods 0.000 description 3
- 239000011135 tin Substances 0.000 description 3
- LDYBCIIYBRKOEL-UHFFFAOYSA-N (7-benzyl-1-methyl-2,6-dioxopurin-3-yl)methyl 2,2-dimethylpropanoate Chemical compound C1=2C(=O)N(C)C(=O)N(COC(=O)C(C)(C)C)C=2N=CN1CC1=CC=CC=C1 LDYBCIIYBRKOEL-UHFFFAOYSA-N 0.000 description 2
- UKGJZDSUJSPAJL-YPUOHESYSA-N (e)-n-[(1r)-1-[3,5-difluoro-4-(methanesulfonamido)phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)pyridin-3-yl]prop-2-enamide Chemical compound CCCC1=NC(C(F)(F)F)=CC=C1\C=C\C(=O)N[C@H](C)C1=CC(F)=C(NS(C)(=O)=O)C(F)=C1 UKGJZDSUJSPAJL-YPUOHESYSA-N 0.000 description 2
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- HUGHCNRRGQMLGZ-UHFFFAOYSA-N 1-but-2-ynyl-2-piperazin-1-yl-6h-imidazo[4,5-d]pyridazin-7-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2C=NNC(=O)C=2N(CC#CC)C=1N1CCNCC1 HUGHCNRRGQMLGZ-UHFFFAOYSA-N 0.000 description 2
- WJFNSKYGHSLTHE-UHFFFAOYSA-N 1-but-2-ynyl-5-cyano-2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]imidazole-4-carboxylic acid Chemical compound OC(=O)C1=C(C#N)N(CC#CC)C(N2CCN(CC2)C(=O)OC(C)(C)C)=N1 WJFNSKYGHSLTHE-UHFFFAOYSA-N 0.000 description 2
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- GZGFUEYYVLJISX-UHFFFAOYSA-N 2-(3-aminopiperidin-1-yl)-3-but-2-ynyl-5-methylimidazo[4,5-d]pyridazin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2C=NN(C)C(=O)C=2N(CC#CC)C=1N1CCCC(N)C1 GZGFUEYYVLJISX-UHFFFAOYSA-N 0.000 description 2
- KGEUIVVNFRMYMN-UHFFFAOYSA-N 2-(7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)oxyacetic acid Chemical compound N=1C=2N=C(OCC(O)=O)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 KGEUIVVNFRMYMN-UHFFFAOYSA-N 0.000 description 2
- PAZDNBCHIOGYBF-UHFFFAOYSA-N 2-(7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)oxybenzamide;hydrochloride Chemical compound Cl.CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1OC1=CC=CC=C1C(N)=O PAZDNBCHIOGYBF-UHFFFAOYSA-N 0.000 description 2
- RBRIKVSIVGHWDR-UHFFFAOYSA-N 2-(7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)sulfanylacetic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(SCC(O)=O)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 RBRIKVSIVGHWDR-UHFFFAOYSA-N 0.000 description 2
- GHWWEKLQJXFCPQ-UHFFFAOYSA-N 2-[7-but-2-ynyl-1-[(3-cyanophenyl)methyl]-6-oxo-8-piperazin-1-ylpurin-2-yl]oxybenzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC(C#N)=CC=1CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1OC1=CC=CC=C1C(N)=O GHWWEKLQJXFCPQ-UHFFFAOYSA-N 0.000 description 2
- QDPVBGCUCRRQIE-UHFFFAOYSA-N 2-[8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-1-methyl-6-oxopurin-2-yl]oxybenzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC#CC)C(N3CC(N)CCC3)=NC=2N=C1OC1=CC=CC=C1C(N)=O QDPVBGCUCRRQIE-UHFFFAOYSA-N 0.000 description 2
- GHDVELTYYYSCAU-UHFFFAOYSA-N 2-[[7-but-2-ynyl-2-(dimethylamino)-6-oxo-8-piperazin-1-ylpurin-1-yl]methyl]benzonitrile;hydrochloride Chemical compound Cl.O=C1C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C(N(C)C)N1CC1=CC=CC=C1C#N GHDVELTYYYSCAU-UHFFFAOYSA-N 0.000 description 2
- OIKJTRFVCZPRQR-UHFFFAOYSA-N 2-bromo-1-but-2-ynylimidazole-4,5-dicarbonitrile Chemical compound CC#CCN1C(Br)=NC(C#N)=C1C#N OIKJTRFVCZPRQR-UHFFFAOYSA-N 0.000 description 2
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 2
- WICQTTXIGYKJOQ-UHFFFAOYSA-N 2-chloro-5-methyl-1H-imidazo[4,5-d]pyridazin-4-one Chemical compound O=C1N(C)N=CC2=C1N=C(Cl)N2 WICQTTXIGYKJOQ-UHFFFAOYSA-N 0.000 description 2
- JKBXWCBGYBOKCQ-UHFFFAOYSA-N 2-chloro-n,n-dimethyl-4-oxo-5-(phenylmethoxymethyl)imidazo[4,5-d]pyridazine-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1C(Cl)=NC(C2=O)=C1C=NN2COCC1=CC=CC=C1 JKBXWCBGYBOKCQ-UHFFFAOYSA-N 0.000 description 2
- BPGIOCZAQDIBPI-UHFFFAOYSA-N 2-ethoxyethanamine Chemical compound CCOCCN BPGIOCZAQDIBPI-UHFFFAOYSA-N 0.000 description 2
- VIHUZJYFQOEUMI-UHFFFAOYSA-N 3-Hydroxypicolinamide Chemical compound NC(=O)C1=NC=CC=C1O VIHUZJYFQOEUMI-UHFFFAOYSA-N 0.000 description 2
- BIEUWRRUZGWNDA-UHFFFAOYSA-N 3-[1-but-2-ynyl-5-cyano-2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]imidazol-4-yl]prop-2-enoic acid Chemical compound OC(=O)C=CC1=C(C#N)N(CC#CC)C(N2CCN(CC2)C(=O)OC(C)(C)C)=N1 BIEUWRRUZGWNDA-UHFFFAOYSA-N 0.000 description 2
- RDNKBLSBOLPNSU-UHFFFAOYSA-N 3-but-2-ynyl-2-chloro-5-methylimidazo[4,5-d]pyridazin-4-one Chemical compound C1=NN(C)C(=O)C2=C1N=C(Cl)N2CC#CC RDNKBLSBOLPNSU-UHFFFAOYSA-N 0.000 description 2
- COMPSUNHVWLFCD-UHFFFAOYSA-N 3-but-2-ynyl-2-piperazin-1-yl-5-prop-2-ynylimidazo[4,5-d]pyridazin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2C=NN(CC#C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 COMPSUNHVWLFCD-UHFFFAOYSA-N 0.000 description 2
- ZBXMPEXQHOLJBP-UHFFFAOYSA-N 3-but-2-ynyl-5-(2-phenylethyl)-2-piperazin-1-ylimidazo[4,5-c]pyridin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1C=2N(CC#CC)C(N3CCNCC3)=NC=2C=CN1CCC1=CC=CC=C1 ZBXMPEXQHOLJBP-UHFFFAOYSA-N 0.000 description 2
- NWHDPWNPZNMWDT-UHFFFAOYSA-N 3-but-2-ynyl-5-(phenylmethoxymethyl)-2-piperazin-1-ylimidazo[4,5-d]pyridazin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1C=2N(CC#CC)C(N3CCNCC3)=NC=2C=NN1COCC1=CC=CC=C1 NWHDPWNPZNMWDT-UHFFFAOYSA-N 0.000 description 2
- NKSCELWIDHUNPO-UHFFFAOYSA-N 3-but-2-ynyl-5-methyl-2-piperazin-1-ylimidazo[4,5-d]pyridazin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2C=NN(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 NKSCELWIDHUNPO-UHFFFAOYSA-N 0.000 description 2
- CNRWNMLACYVFBA-UHFFFAOYSA-N 3-but-2-ynyl-5-methyl-4-oxo-2-piperazin-1-ylimidazo[4,5-d]pyridazine-7-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2C(C(N)=O)=NN(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 CNRWNMLACYVFBA-UHFFFAOYSA-N 0.000 description 2
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- MAJRKXRECIWBPB-UHFFFAOYSA-N 5-(phenylmethoxymethyl)-1H-imidazo[4,5-d]pyridazin-4-one Chemical compound N1=CC=2NC=NC=2C(=O)N1COCC1=CC=CC=C1 MAJRKXRECIWBPB-UHFFFAOYSA-N 0.000 description 2
- PNXODGIDMSYKSD-UHFFFAOYSA-N 5-methyl-1-tritylimidazo[4,5-d]pyridazin-4-one Chemical compound C1=NC=2C(=O)N(C)N=CC=2N1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 PNXODGIDMSYKSD-UHFFFAOYSA-N 0.000 description 2
- HEQMOCFQZNOIGX-UHFFFAOYSA-N 5-methyl-1H-imidazo[4,5-d]pyridazin-4-one Chemical compound O=C1N(C)N=CC2=C1N=CN2 HEQMOCFQZNOIGX-UHFFFAOYSA-N 0.000 description 2
- QIOLZZDIEDAGPJ-UHFFFAOYSA-N 7-benzyl-1-methyl-8-piperazin-1-ylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)C=NC=2N=C1N1CCNCC1 QIOLZZDIEDAGPJ-UHFFFAOYSA-N 0.000 description 2
- QOYGLSWWXXBIGG-UHFFFAOYSA-N 7-benzyl-3h-purin-6-one Chemical compound C1=2C(=O)N=CNC=2N=CN1CC1=CC=CC=C1 QOYGLSWWXXBIGG-UHFFFAOYSA-N 0.000 description 2
- XDUTVTQACWYOMX-UHFFFAOYSA-N 7-benzyl-3h-purine-2,6-dione Chemical compound C1=2C(=O)NC(=O)NC=2N=CN1CC1=CC=CC=C1 XDUTVTQACWYOMX-UHFFFAOYSA-N 0.000 description 2
- GRYHQACENKWSAF-UHFFFAOYSA-N 7-but-2-ynyl-1-[(2-cyanophenyl)methyl]-6-oxo-8-piperazin-1-ylpurine-2-carbonitrile;hydrochloride Chemical compound Cl.O=C1C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C(C#N)N1CC1=CC=CC=C1C#N GRYHQACENKWSAF-UHFFFAOYSA-N 0.000 description 2
- MJKVNQQJEZALNY-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-3h-purine-2,6-dione Chemical compound N1C(=O)N(C)C(=O)C2=C1N=CN2CC#CC MJKVNQQJEZALNY-UHFFFAOYSA-N 0.000 description 2
- IWVBXYPLWJJKTJ-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurine-2-carboxamide Chemical compound N=1C=2N=C(C(N)=O)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 IWVBXYPLWJJKTJ-UHFFFAOYSA-N 0.000 description 2
- BSBKBIUKBYTTFP-UHFFFAOYSA-N 7-but-2-ynyl-2-methoxy-1-(2-phenylethyl)-8-piperazin-1-ylpurin-6-one;hydrochloride Chemical compound Cl.CC#CCN1C=2C(=O)N(CCC=3C=CC=CC=3)C(OC)=NC=2N=C1N1CCNCC1 BSBKBIUKBYTTFP-UHFFFAOYSA-N 0.000 description 2
- FTWYDFUIDNRMSE-UHFFFAOYSA-N 7-but-2-ynyl-2-methoxy-1-methyl-8-piperazin-1-ylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC#CCN1C=2C(=O)N(C)C(OC)=NC=2N=C1N1CCNCC1 FTWYDFUIDNRMSE-UHFFFAOYSA-N 0.000 description 2
- KNUCUUGOPBGLBO-UHFFFAOYSA-N 7-but-2-ynyl-8-chloro-1,3-dimethylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=C(Cl)N2CC#CC KNUCUUGOPBGLBO-UHFFFAOYSA-N 0.000 description 2
- NZWYYVPCBRSLHE-UHFFFAOYSA-N 8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-1-[(2-cyanophenyl)methyl]-6-oxopurine-2-carbonitrile;hydrochloride Chemical compound Cl.O=C1C=2N(CC#CC)C(N3CC(N)CCC3)=NC=2N=C(C#N)N1CC1=CC=CC=C1C#N NZWYYVPCBRSLHE-UHFFFAOYSA-N 0.000 description 2
- URVMEEPQNQUOCK-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl 3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidine-1-carboxylate Chemical compound C1C(NC(=O)OC(C)(C)C)CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 URVMEEPQNQUOCK-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- WTBNKROSXQAYHP-UHFFFAOYSA-N [7-benzyl-2,6-dioxo-1-(2-phenylethyl)purin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound C1=2C(=O)N(CCC=3C=CC=CC=3)C(=O)N(COC(=O)C(C)(C)C)C=2N=CN1CC1=CC=CC=C1 WTBNKROSXQAYHP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- UYJXRRSPUVSSMN-UHFFFAOYSA-P ammonium sulfide Chemical compound [NH4+].[NH4+].[S-2] UYJXRRSPUVSSMN-UHFFFAOYSA-P 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- SIONIIVXRCVHFL-UHFFFAOYSA-N benzyl 3-[(2-methylpropan-2-yl)oxycarbonylamino]piperidine-1-carboxylate Chemical compound C1C(NC(=O)OC(C)(C)C)CCCN1C(=O)OCC1=CC=CC=C1 SIONIIVXRCVHFL-UHFFFAOYSA-N 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical class [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
- 239000001354 calcium citrate Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000012320 chlorinating reagent Substances 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 2
- 230000020335 dealkylation Effects 0.000 description 2
- 238000006900 dealkylation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- BPKWPOQMUZRSND-UHFFFAOYSA-N ethyl 2-(7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)oxyacetate Chemical compound CC#CCN1C=2C(=O)N(C)C(OCC(=O)OCC)=NC=2N=C1N1CCNCC1 BPKWPOQMUZRSND-UHFFFAOYSA-N 0.000 description 2
- KYNRWLVLFYXXQQ-UHFFFAOYSA-N ethyl 2-(7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)oxyacetate 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC#CCN1C=2C(=O)N(C)C(OCC(=O)OCC)=NC=2N=C1N1CCNCC1 KYNRWLVLFYXXQQ-UHFFFAOYSA-N 0.000 description 2
- VKECBACTQDLHGF-UHFFFAOYSA-N ethyl 2-[7-(2-chlorophenyl)-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl]oxyacetate 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=C(Cl)C=1N1C=2C(=O)N(C)C(OCC(=O)OCC)=NC=2N=C1N1CCNCC1 VKECBACTQDLHGF-UHFFFAOYSA-N 0.000 description 2
- KSSINHDEAXFKGB-UHFFFAOYSA-N ethyl 2-bromo-1-but-2-ynyl-5-cyanoimidazole-4-carboxylate Chemical compound CCOC(=O)C=1N=C(Br)N(CC#CC)C=1C#N KSSINHDEAXFKGB-UHFFFAOYSA-N 0.000 description 2
- HKFKJOKMFLBULX-UHFFFAOYSA-N ethyl 2-bromo-3-but-2-ynyl-5-cyanoimidazole-4-carboxylate Chemical compound CCOC(=O)C1=C(C#N)N=C(Br)N1CC#CC HKFKJOKMFLBULX-UHFFFAOYSA-N 0.000 description 2
- 239000012025 fluorinating agent Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- JKFAIQOWCVVSKC-UHFFFAOYSA-N furazan Chemical group C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000007866 imination reaction Methods 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 2
- HQEIPVHJHZTMDP-NUBCRITNSA-N methyl (2r)-pyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.COC(=O)[C@H]1CCCN1 HQEIPVHJHZTMDP-NUBCRITNSA-N 0.000 description 2
- WURDMHABRQUGLR-UHFFFAOYSA-N methyl 2-[2-(7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)oxyphenyl]acetate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC(=O)CC1=CC=CC=C1OC(N(C1=O)C)=NC2=C1N(CC#CC)C(N1CCNCC1)=N2 WURDMHABRQUGLR-UHFFFAOYSA-N 0.000 description 2
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 2
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 2
- QJFODBVFHIFSHY-UHFFFAOYSA-N n,n-dimethyl-4-oxo-5-(phenylmethoxymethyl)imidazo[4,5-d]pyridazine-1-sulfonamide Chemical compound CN(C)S(=O)(=O)N1C=NC(C2=O)=C1C=NN2COCC1=CC=CC=C1 QJFODBVFHIFSHY-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 2
- 150000002826 nitrites Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- SUVIGLJNEAMWEG-UHFFFAOYSA-N propane-1-thiol Chemical compound CCCS SUVIGLJNEAMWEG-UHFFFAOYSA-N 0.000 description 2
- KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004526 pyridazin-2-yl group Chemical group N1N(C=CC=C1)* 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000003979 response to food Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- LUZQWIDBCBECFY-UHFFFAOYSA-N tert-butyl 4-(1-but-2-ynyl-4-carbamothioyl-5-ethoxycarbonylimidazol-2-yl)piperazine-1-carboxylate Chemical compound CC#CCN1C(C(=O)OCC)=C(C(N)=S)N=C1N1CCN(C(=O)OC(C)(C)C)CC1 LUZQWIDBCBECFY-UHFFFAOYSA-N 0.000 description 2
- MRXLPCMJTVKIDR-UHFFFAOYSA-N tert-butyl 4-(1-but-2-ynyl-5-cyano-4-ethoxycarbonylimidazol-2-yl)piperazine-1-carboxylate Chemical compound CC#CCN1C(C#N)=C(C(=O)OCC)N=C1N1CCN(C(=O)OC(C)(C)C)CC1 MRXLPCMJTVKIDR-UHFFFAOYSA-N 0.000 description 2
- AMWYRBBENXEKDD-UHFFFAOYSA-N tert-butyl 4-(1-but-2-ynyl-5-cyano-4-formylimidazol-2-yl)piperazine-1-carboxylate Chemical compound O=CC1=C(C#N)N(CC#CC)C(N2CCN(CC2)C(=O)OC(C)(C)C)=N1 AMWYRBBENXEKDD-UHFFFAOYSA-N 0.000 description 2
- HGOWXQZCPLWSAF-UHFFFAOYSA-N tert-butyl 4-(1-but-2-ynyl-5-ethoxycarbonyl-4-formylimidazol-2-yl)piperazine-1-carboxylate Chemical compound CC#CCN1C(C(=O)OCC)=C(C=O)N=C1N1CCN(C(=O)OC(C)(C)C)CC1 HGOWXQZCPLWSAF-UHFFFAOYSA-N 0.000 description 2
- FTWAAONEHXCFSK-UHFFFAOYSA-N tert-butyl 4-(1-but-2-ynyl-5-ethoxycarbonyl-4-methylsulfanylcarbonylimidazol-2-yl)piperazine-1-carboxylate Chemical compound CC#CCN1C(C(=O)OCC)=C(C(=O)SC)N=C1N1CCN(C(=O)OC(C)(C)C)CC1 FTWAAONEHXCFSK-UHFFFAOYSA-N 0.000 description 2
- QSCWNSBXSQPHKV-UHFFFAOYSA-N tert-butyl 4-(5-methyl-4-oxo-1H-imidazo[4,5-d]pyridazin-2-yl)piperazine-1-carboxylate Chemical compound N1C=2C(=O)N(C)N=CC=2N=C1N1CCN(C(=O)OC(C)(C)C)CC1 QSCWNSBXSQPHKV-UHFFFAOYSA-N 0.000 description 2
- SMBCRGJDQAUIRZ-UHFFFAOYSA-N tert-butyl 4-(7-benzyl-6-oxo-3h-purin-8-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)NC=N2 SMBCRGJDQAUIRZ-UHFFFAOYSA-N 0.000 description 2
- BVUZOCFODKVALZ-UHFFFAOYSA-N tert-butyl 4-(7-but-2-ynyl-1,3-dimethyl-2,6-dioxopurin-8-yl)piperazine-1-carboxylate Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(CC#CC)C=1N1CCN(C(=O)OC(C)(C)C)CC1 BVUZOCFODKVALZ-UHFFFAOYSA-N 0.000 description 2
- ADYIYJATSSKFKN-UHFFFAOYSA-N tert-butyl 4-(7-but-2-ynyl-2-carbamoyl-1-methyl-6-oxopurin-8-yl)piperazine-1-carboxylate Chemical compound N=1C=2N=C(C(N)=O)N(C)C(=O)C=2N(CC#CC)C=1N1CCN(C(=O)OC(C)(C)C)CC1 ADYIYJATSSKFKN-UHFFFAOYSA-N 0.000 description 2
- MWZONKBOYKVTHA-UHFFFAOYSA-N tert-butyl 4-[1-but-2-ynyl-4-[cyano(hydroxy)methyl]-5-methoxycarbonylimidazol-2-yl]piperazine-1-carboxylate Chemical compound CC#CCN1C(C(=O)OC)=C(C(O)C#N)N=C1N1CCN(C(=O)OC(C)(C)C)CC1 MWZONKBOYKVTHA-UHFFFAOYSA-N 0.000 description 2
- YBFGSUBTYFTOAX-UHFFFAOYSA-N tert-butyl 4-[1-but-2-ynyl-5-carbamoyl-4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethenyl]imidazol-2-yl]piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)NC=CC1=C(C(N)=O)N(CC#CC)C(N2CCN(CC2)C(=O)OC(C)(C)C)=N1 YBFGSUBTYFTOAX-UHFFFAOYSA-N 0.000 description 2
- KRJWCXUMGFQFJE-UHFFFAOYSA-N tert-butyl 4-[1-but-2-ynyl-5-cyano-4-(3-ethoxy-3-oxoprop-1-enyl)imidazol-2-yl]piperazine-1-carboxylate Chemical compound CC#CCN1C(C#N)=C(C=CC(=O)OCC)N=C1N1CCN(C(=O)OC(C)(C)C)CC1 KRJWCXUMGFQFJE-UHFFFAOYSA-N 0.000 description 2
- ZWEMEPJPSNHVRA-UHFFFAOYSA-N tert-butyl 4-[1-but-2-ynyl-5-cyano-4-(hydroxymethyl)imidazol-2-yl]piperazine-1-carboxylate Chemical compound OCC1=C(C#N)N(CC#CC)C(N2CCN(CC2)C(=O)OC(C)(C)C)=N1 ZWEMEPJPSNHVRA-UHFFFAOYSA-N 0.000 description 2
- XNEFSIQZPQBKOD-UHFFFAOYSA-N tert-butyl 4-[1-but-2-ynyl-5-cyano-4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethenyl]imidazol-2-yl]piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)NC=CC1=C(C#N)N(CC#CC)C(N2CCN(CC2)C(=O)OC(C)(C)C)=N1 XNEFSIQZPQBKOD-UHFFFAOYSA-N 0.000 description 2
- MWMFSWHXCLYDKX-UHFFFAOYSA-N tert-butyl 4-[1-but-2-ynyl-5-ethoxycarbonyl-4-(c-methylsulfanylcarbonimidoyl)imidazol-2-yl]piperazine-1-carboxylate Chemical compound CC#CCN1C(C(=O)OCC)=C(C(=N)SC)N=C1N1CCN(C(=O)OC(C)(C)C)CC1 MWMFSWHXCLYDKX-UHFFFAOYSA-N 0.000 description 2
- IVUJUEAKTIQKCZ-UHFFFAOYSA-N tert-butyl 4-[1-but-2-ynyl-5-ethoxycarbonyl-4-(hydroxymethyl)imidazol-2-yl]piperazine-1-carboxylate Chemical compound CC#CCN1C(C(=O)OCC)=C(CO)N=C1N1CCN(C(=O)OC(C)(C)C)CC1 IVUJUEAKTIQKCZ-UHFFFAOYSA-N 0.000 description 2
- ANIHKRWBKRYJSP-UHFFFAOYSA-N tert-butyl 4-[3-benzyl-4-oxo-5-(phenylmethoxymethyl)imidazo[4,5-d]pyridazin-2-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(N1CC=2C=CC=CC=2)=NC2=C1C(=O)N(COCC=1C=CC=CC=1)N=C2 ANIHKRWBKRYJSP-UHFFFAOYSA-N 0.000 description 2
- FRTUZXLLAVXVRI-UHFFFAOYSA-N tert-butyl 4-[4-(2-amino-1-hydroxy-2-oxoethyl)-1-but-2-ynyl-5-methoxycarbonylimidazol-2-yl]piperazine-1-carboxylate Chemical compound CC#CCN1C(C(=O)OC)=C(C(O)C(N)=O)N=C1N1CCN(C(=O)OC(C)(C)C)CC1 FRTUZXLLAVXVRI-UHFFFAOYSA-N 0.000 description 2
- GGHJQESFLNUKPG-UHFFFAOYSA-N tert-butyl 4-[7-(2-chlorophenyl)-1-methyl-2,6-dioxo-3h-purin-8-yl]piperazine-1-carboxylate Chemical compound C=1C=CC=C(Cl)C=1N1C=2C(=O)N(C)C(=O)NC=2N=C1N1CCN(C(=O)OC(C)(C)C)CC1 GGHJQESFLNUKPG-UHFFFAOYSA-N 0.000 description 2
- BGTXNPUMKNACIX-UHFFFAOYSA-N tert-butyl 4-[7-(2-chlorophenyl)-3-(2,2-dimethylpropanoyloxymethyl)-1-methyl-2,6-dioxopurin-8-yl]piperazine-1-carboxylate Chemical compound C=1C=CC=C(Cl)C=1N1C=2C(=O)N(C)C(=O)N(COC(=O)C(C)(C)C)C=2N=C1N1CCN(C(=O)OC(C)(C)C)CC1 BGTXNPUMKNACIX-UHFFFAOYSA-N 0.000 description 2
- WJNMQASULXZNJA-UHFFFAOYSA-N tert-butyl 4-[7-but-2-ynyl-1-[(2-cyanophenyl)methyl]-2-(dimethylamino)-6-oxopurin-8-yl]piperazine-1-carboxylate Chemical compound O=C1C=2N(CC#CC)C(N3CCN(CC3)C(=O)OC(C)(C)C)=NC=2N=C(N(C)C)N1CC1=CC=CC=C1C#N WJNMQASULXZNJA-UHFFFAOYSA-N 0.000 description 2
- IYMJDEBSFXOPFX-UHFFFAOYSA-N tert-butyl 4-[7-but-2-ynyl-2,6-dioxo-1-(2-phenylethyl)-3h-purin-8-yl]piperazine-1-carboxylate Chemical compound O=C1C=2N(CC#CC)C(N3CCN(CC3)C(=O)OC(C)(C)C)=NC=2NC(=O)N1CCC1=CC=CC=C1 IYMJDEBSFXOPFX-UHFFFAOYSA-N 0.000 description 2
- NNDDOXXQHPTJKE-UHFFFAOYSA-N tert-butyl 4-[7-but-2-ynyl-2-chloro-1-[(3-cyanophenyl)methyl]-6-oxopurin-8-yl]piperazine-1-carboxylate Chemical compound O=C1C=2N(CC#CC)C(N3CCN(CC3)C(=O)OC(C)(C)C)=NC=2N=C(Cl)N1CC1=CC=CC(C#N)=C1 NNDDOXXQHPTJKE-UHFFFAOYSA-N 0.000 description 2
- QCLWNOVVTREOAB-UHFFFAOYSA-N tert-butyl 4-[7-but-2-ynyl-2-chloro-1-[(4-cyanophenyl)methyl]-6-oxopurin-8-yl]piperazine-1-carboxylate Chemical compound O=C1C=2N(CC#CC)C(N3CCN(CC3)C(=O)OC(C)(C)C)=NC=2N=C(Cl)N1CC1=CC=C(C#N)C=C1 QCLWNOVVTREOAB-UHFFFAOYSA-N 0.000 description 2
- YICLJVMFKJUXFR-UHFFFAOYSA-N tert-butyl 4-[7-but-2-ynyl-2-chloro-6-oxo-1-(2-phenylethyl)purin-8-yl]piperazine-1-carboxylate Chemical compound O=C1C=2N(CC#CC)C(N3CCN(CC3)C(=O)OC(C)(C)C)=NC=2N=C(Cl)N1CCC1=CC=CC=C1 YICLJVMFKJUXFR-UHFFFAOYSA-N 0.000 description 2
- WEHDKJAQYHHAKE-UHFFFAOYSA-N tert-butyl 4-[7-but-2-ynyl-2-cyano-1-[(2-cyanophenyl)methyl]-6-oxopurin-8-yl]piperazine-1-carboxylate Chemical compound O=C1C=2N(CC#CC)C(N3CCN(CC3)C(=O)OC(C)(C)C)=NC=2N=C(C#N)N1CC1=CC=CC=C1C#N WEHDKJAQYHHAKE-UHFFFAOYSA-N 0.000 description 2
- OCVFAPLOXXJMHY-UHFFFAOYSA-N tert-butyl 5-methyl-4-oxoimidazo[4,5-d]pyridazine-1-carboxylate Chemical compound O=C1N(C)N=CC2=C1N=CN2C(=O)OC(C)(C)C OCVFAPLOXXJMHY-UHFFFAOYSA-N 0.000 description 2
- MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 2
- DFROGOVLKYFOGZ-UHFFFAOYSA-N tert-butyl n-[1-(7-but-2-ynyl-2,6-dichloropurin-8-yl)piperidin-3-yl]carbamate Chemical compound N=1C2=NC(Cl)=NC(Cl)=C2N(CC#CC)C=1N1CCCC(NC(=O)OC(C)(C)C)C1 DFROGOVLKYFOGZ-UHFFFAOYSA-N 0.000 description 2
- NTQIOJWZJVAXOB-UHFFFAOYSA-N tert-butyl n-[1-(7-but-2-ynyl-2-chloro-1-methyl-6-oxopurin-8-yl)piperidin-3-yl]carbamate Chemical compound N=1C=2N=C(Cl)N(C)C(=O)C=2N(CC#CC)C=1N1CCCC(NC(=O)OC(C)(C)C)C1 NTQIOJWZJVAXOB-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical group C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000013337 tricalcium citrate Nutrition 0.000 description 2
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 2
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 2
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- RRCMGJCFMJBHQC-UHFFFAOYSA-N (2-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1Cl RRCMGJCFMJBHQC-UHFFFAOYSA-N 0.000 description 1
- KYLUAQBYONVMCP-UHFFFAOYSA-N (2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P KYLUAQBYONVMCP-UHFFFAOYSA-N 0.000 description 1
- CZZWVNXKRMARDW-BTQNPOSSSA-N (2r)-1-(7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)pyrrolidine-2-carboxylic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1N1CCC[C@@H]1C(O)=O CZZWVNXKRMARDW-BTQNPOSSSA-N 0.000 description 1
- CZZWVNXKRMARDW-ZOWNYOTGSA-N (2s)-1-(7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)pyrrolidine-2-carboxylic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1N1CCC[C@H]1C(O)=O CZZWVNXKRMARDW-ZOWNYOTGSA-N 0.000 description 1
- ZOUUXALGMWJKRO-UHFFFAOYSA-N (7-but-2-ynyl-1-methyl-2,6-dioxopurin-3-yl)methyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCN1C(=O)N(C)C(=O)C2=C1N=CN2CC#CC ZOUUXALGMWJKRO-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- USVVENVKYJZFMW-ONEGZZNKSA-N (e)-carboxyiminocarbamic acid Chemical compound OC(=O)\N=N\C(O)=O USVVENVKYJZFMW-ONEGZZNKSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical group C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- WTAPZWXVSZMMDG-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 WTAPZWXVSZMMDG-UHFFFAOYSA-N 0.000 description 1
- ZPTDAGNNHHXAIL-UHFFFAOYSA-N 1,7-bis(but-2-ynyl)-3-methyl-8-piperazin-1-ylpurine-2,6-dione;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N(C)C(=O)N(CC#CC)C(=O)C=2N(CC#CC)C=1N1CCNCC1 ZPTDAGNNHHXAIL-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical group N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- FINXGQXNIBNREL-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethoxycarbonyl)piperidine-3-carboxylic acid Chemical compound C1C(C(=O)O)CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 FINXGQXNIBNREL-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- MMYKTRPLXXWLBC-UHFFFAOYSA-N 1-bromo-2-ethoxyethane Chemical compound CCOCCBr MMYKTRPLXXWLBC-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- IAPQYJWHSSIDMN-UHFFFAOYSA-N 1-cycloundecyl-1,2-diazacycloundec-7-ene Chemical compound C1CCCCCC(CCCC1)N1CCCC=CCCCCN1 IAPQYJWHSSIDMN-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- NCCCTQRHFVSOMP-UHFFFAOYSA-N 1-thiophen-2-ylethanethiol Chemical compound CC(S)C1=CC=CS1 NCCCTQRHFVSOMP-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical group C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- BDWGFPQARAYKOY-UHFFFAOYSA-N 2-(7-but-2-ynyl-3-methyl-2,6-dioxo-8-piperazin-1-ylpurin-1-yl)acetonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N(C)C(=O)N(CC#N)C(=O)C=2N(CC#CC)C=1N1CCNCC1 BDWGFPQARAYKOY-UHFFFAOYSA-N 0.000 description 1
- QCKKUQZIPJBLQF-UHFFFAOYSA-N 2-(bromomethyl)-3-fluorobenzonitrile Chemical compound FC1=CC=CC(C#N)=C1CBr QCKKUQZIPJBLQF-UHFFFAOYSA-N 0.000 description 1
- UDGJABJDSNAELD-UHFFFAOYSA-N 2-[(3-but-2-ynyl-4-oxo-2-piperazin-1-ylimidazo[4,5-d]pyridazin-5-yl)methyl]-3-fluorobenzonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1C=2N(CC#CC)C(N3CCNCC3)=NC=2C=NN1CC1=C(F)C=CC=C1C#N UDGJABJDSNAELD-UHFFFAOYSA-N 0.000 description 1
- SUSACEJKMOPOOD-UHFFFAOYSA-N 2-[(3-but-2-ynyl-4-oxo-2-piperazin-1-ylimidazo[4,5-d]pyridazin-5-yl)methyl]benzonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1C=2N(CC#CC)C(N3CCNCC3)=NC=2C=NN1CC1=CC=CC=C1C#N SUSACEJKMOPOOD-UHFFFAOYSA-N 0.000 description 1
- CCOQBMRQWSMKHH-UHFFFAOYSA-N 2-[(7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)amino]propanoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(NC(C)C(O)=O)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 CCOQBMRQWSMKHH-UHFFFAOYSA-N 0.000 description 1
- PTXUUPOFJJDGQH-UHFFFAOYSA-N 2-[(7-but-2-ynyl-2-methoxy-6-oxo-8-piperazin-1-ylpurin-1-yl)methyl]benzonitrile;hydrochloride Chemical compound Cl.CC#CCN1C=2C(=O)N(CC=3C(=CC=CC=3)C#N)C(OC)=NC=2N=C1N1CCNCC1 PTXUUPOFJJDGQH-UHFFFAOYSA-N 0.000 description 1
- RVZQDLJIMIITEW-UHFFFAOYSA-N 2-[7-but-2-ynyl-1-[(2-cyanophenyl)methyl]-6-oxo-8-piperazin-1-ylpurin-2-yl]oxybenzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=C(C#N)C=1CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1OC1=CC=CC=C1C(N)=O RVZQDLJIMIITEW-UHFFFAOYSA-N 0.000 description 1
- ZNSFMUYEMNKSAH-UHFFFAOYSA-N 2-[7-but-2-ynyl-1-[(4-cyanophenyl)methyl]-6-oxo-8-piperazin-1-ylpurin-2-yl]oxybenzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=C(C#N)C=CC=1CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1OC1=CC=CC=C1C(N)=O ZNSFMUYEMNKSAH-UHFFFAOYSA-N 0.000 description 1
- YYTJDDYXBQEZTJ-UHFFFAOYSA-N 2-[[8-(3-aminopiperidin-1-yl)-7-but-2-ynyl-2-methoxy-6-oxopurin-1-yl]methyl]benzonitrile;hydrochloride Chemical compound Cl.CC#CCN1C=2C(=O)N(CC=3C(=CC=CC=3)C#N)C(OC)=NC=2N=C1N1CCCC(N)C1 YYTJDDYXBQEZTJ-UHFFFAOYSA-N 0.000 description 1
- IOOHBIFQNQQUFI-UHFFFAOYSA-N 2-bromo-1-(3-methoxyphenyl)ethanone Chemical compound COC1=CC=CC(C(=O)CBr)=C1 IOOHBIFQNQQUFI-UHFFFAOYSA-N 0.000 description 1
- JJFOBACUIRKUPN-UHFFFAOYSA-N 2-bromoethoxybenzene Chemical compound BrCCOC1=CC=CC=C1 JJFOBACUIRKUPN-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2h-imidazo[4,5-d][1,3]thiazole Chemical group C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 description 1
- GAKJDUZJDUHTAF-UHFFFAOYSA-N 3-(7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)sulfanylpropanoic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(SCCC(O)=O)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 GAKJDUZJDUHTAF-UHFFFAOYSA-N 0.000 description 1
- CVKOOKPNCVYHNY-UHFFFAOYSA-N 3-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=CC(C#N)=C1 CVKOOKPNCVYHNY-UHFFFAOYSA-N 0.000 description 1
- HOKDHOSQTUSEGZ-UHFFFAOYSA-N 3-[7-but-2-ynyl-1-[(2-cyanophenyl)methyl]-6-oxo-8-piperazin-1-ylpurin-2-yl]oxypyridine-2-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=C(C#N)C=1CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1OC1=CC=CN=C1C(N)=O HOKDHOSQTUSEGZ-UHFFFAOYSA-N 0.000 description 1
- PORWKJHACATUHR-UHFFFAOYSA-N 3-benzyl-5-(2-phenylethyl)-2-piperazin-1-ylimidazo[4,5-d]pyridazin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=CC=2N=C(N3CCNCC3)N(CC=3C=CC=CC=3)C=2C(=O)N1CCC1=CC=CC=C1 PORWKJHACATUHR-UHFFFAOYSA-N 0.000 description 1
- LNGNIZIPHZLMMX-UHFFFAOYSA-N 3-benzyl-5-methyl-2-piperazin-1-ylimidazo[4,5-d]pyridazin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C=1C=CC=CC=1CN1C=2C(=O)N(C)N=CC=2N=C1N1CCNCC1 LNGNIZIPHZLMMX-UHFFFAOYSA-N 0.000 description 1
- QYTGWDLJKAURRR-UHFFFAOYSA-N 3-but-2-ynyl-5-(2-phenoxyethyl)-2-piperazin-1-ylimidazo[4,5-c]pyridin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1C=2N(CC#CC)C(N3CCNCC3)=NC=2C=CN1CCOC1=CC=CC=C1 QYTGWDLJKAURRR-UHFFFAOYSA-N 0.000 description 1
- BUEQZAQCMZIKKQ-UHFFFAOYSA-N 3-but-2-ynyl-5-[2-(3-methoxyphenyl)-2-oxoethyl]-2-piperazin-1-ylimidazo[4,5-d]pyridazin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC1=CC=CC(C(=O)CN2C(C=3N(CC#CC)C(N4CCNCC4)=NC=3C=N2)=O)=C1 BUEQZAQCMZIKKQ-UHFFFAOYSA-N 0.000 description 1
- SHNMWMHQYGPYQN-UHFFFAOYSA-N 3-but-2-ynyl-5-cyano-4-ethoxy-2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]-1H-imidazole-2-carboxylic acid Chemical compound C(C#CC)N1C(NC(=C1OCC)C#N)(N1CCN(CC1)C(=O)OC(C)(C)C)C(=O)O SHNMWMHQYGPYQN-UHFFFAOYSA-N 0.000 description 1
- LZGFSQGUWDOWGL-UHFFFAOYSA-N 3-but-2-ynyl-5-phenacyl-2-piperazin-1-ylimidazo[4,5-c]pyridin-4-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O=C1C=2N(CC#CC)C(N3CCNCC3)=NC=2C=CN1CC(=O)C1=CC=CC=C1 LZGFSQGUWDOWGL-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- OCVLSHAVSIYKLI-UHFFFAOYSA-N 3h-1,3-thiazole-2-thione Chemical compound SC1=NC=CS1 OCVLSHAVSIYKLI-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical group O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- NLHAIPFBNQZTMY-UHFFFAOYSA-N 4-methyl-3h-1,3-thiazole-2-thione Chemical compound CC1=CSC(S)=N1 NLHAIPFBNQZTMY-UHFFFAOYSA-N 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 1
- DVGNXXNMFUSOTC-UHFFFAOYSA-N 7-benzyl-8-chloro-3h-purin-6-one Chemical compound ClC1=NC=2N=CNC(=O)C=2N1CC1=CC=CC=C1 DVGNXXNMFUSOTC-UHFFFAOYSA-N 0.000 description 1
- GWHBIRKQKVBVJE-UHFFFAOYSA-N 7-but-2-ynyl-1,2-dimethyl-8-piperazin-1-ylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(C)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 GWHBIRKQKVBVJE-UHFFFAOYSA-N 0.000 description 1
- OUOMOGARIJBFJO-UHFFFAOYSA-N 7-but-2-ynyl-1-(2-ethoxyethyl)-3-methyl-8-piperazin-1-ylpurine-2,6-dione;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC#CCN1C=2C(=O)N(CCOCC)C(=O)N(C)C=2N=C1N1CCNCC1 OUOMOGARIJBFJO-UHFFFAOYSA-N 0.000 description 1
- CVZQGHRVBOHGIG-UHFFFAOYSA-N 7-but-2-ynyl-1-ethyl-3-methyl-8-piperazin-1-ylpurine-2,6-dione;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC#CCN1C=2C(=O)N(CC)C(=O)N(C)C=2N=C1N1CCNCC1 CVZQGHRVBOHGIG-UHFFFAOYSA-N 0.000 description 1
- UTJBQEYZKFYSOI-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-2-(1-methylimidazol-2-yl)sulfanyl-8-piperazin-1-ylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1SC1=NC=CN1C UTJBQEYZKFYSOI-UHFFFAOYSA-N 0.000 description 1
- LHMRTQNWTPQXBA-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-2-[(4-methyl-1,3-thiazol-2-yl)sulfanyl]-8-piperazin-1-ylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1SC1=NC(C)=CS1 LHMRTQNWTPQXBA-UHFFFAOYSA-N 0.000 description 1
- XBPRGKOVENKEBF-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-2-phenoxy-8-piperazin-1-ylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1OC1=CC=CC=C1 XBPRGKOVENKEBF-UHFFFAOYSA-N 0.000 description 1
- ZOJJUNBBFWKUQE-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurine-2-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(C#N)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 ZOJJUNBBFWKUQE-UHFFFAOYSA-N 0.000 description 1
- KDFCOKOCQVUHIM-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-8-piperazin-1-yl-2-(1,3-thiazol-2-ylsulfanyl)purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1SC1=NC=CS1 KDFCOKOCQVUHIM-UHFFFAOYSA-N 0.000 description 1
- KNLOSJMPIDABNN-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-8-piperazin-1-yl-2-(1-thiophen-2-ylethylsulfanyl)purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1SC(C)C1=CC=CS1 KNLOSJMPIDABNN-UHFFFAOYSA-N 0.000 description 1
- DCLPADJWXFURKX-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-8-piperazin-1-yl-2-propan-2-ylsulfanylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(SC(C)C)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 DCLPADJWXFURKX-UHFFFAOYSA-N 0.000 description 1
- DQGBBPBSKZNUJM-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-8-piperazin-1-yl-2-propylsulfanylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC#CCN1C=2C(=O)N(C)C(SCCC)=NC=2N=C1N1CCNCC1 DQGBBPBSKZNUJM-UHFFFAOYSA-N 0.000 description 1
- UXCZTIQCKWMMEY-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-8-piperazin-1-yl-2-pyridin-2-ylsulfanylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1SC1=CC=CC=N1 UXCZTIQCKWMMEY-UHFFFAOYSA-N 0.000 description 1
- LGFGFRAARUEMQS-UHFFFAOYSA-N 7-but-2-ynyl-1-methyl-8-piperazin-1-yl-2-sulfanylidene-3h-purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2NC(=S)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 LGFGFRAARUEMQS-UHFFFAOYSA-N 0.000 description 1
- TVFJCPYHMATCIG-UHFFFAOYSA-N 7-but-2-ynyl-2-(2-ethoxyethylamino)-1-methyl-8-piperazin-1-ylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC#CCN1C=2C(=O)N(C)C(NCCOCC)=NC=2N=C1N1CCNCC1 TVFJCPYHMATCIG-UHFFFAOYSA-N 0.000 description 1
- NMIZSOSZGRBSIC-UHFFFAOYSA-N 7-but-2-ynyl-2-(dimethylamino)-1-methyl-8-piperazin-1-ylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N=C(N(C)C)N(C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 NMIZSOSZGRBSIC-UHFFFAOYSA-N 0.000 description 1
- PHKDHGIGQTYVHE-UHFFFAOYSA-N 7-but-2-ynyl-2-chloro-8-piperazin-1-yl-3h-purin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2NC(Cl)=NC(=O)C=2N(CC#CC)C=1N1CCNCC1 PHKDHGIGQTYVHE-UHFFFAOYSA-N 0.000 description 1
- AZOQJVTVJATWAG-UHFFFAOYSA-N 7-but-2-ynyl-2-cyclopentyloxy-1-methyl-8-piperazin-1-ylpurin-6-one;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN1C(=O)C=2N(CC#CC)C(N3CCNCC3)=NC=2N=C1OC1CCCC1 AZOQJVTVJATWAG-UHFFFAOYSA-N 0.000 description 1
- FEUSIMLGQPEQDH-UHFFFAOYSA-N 7-but-2-ynyl-2-ethoxy-1-methyl-8-piperazin-1-ylpurin-6-one Chemical compound CC#CCN1C=2C(=O)N(C)C(OCC)=NC=2N=C1N1CCNCC1 FEUSIMLGQPEQDH-UHFFFAOYSA-N 0.000 description 1
- VVNHSWZPXMZLEF-UHFFFAOYSA-N 7-but-2-ynyl-3-methyl-8-piperazin-1-yl-1-prop-2-ynylpurine-2,6-dione;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N=1C=2N(C)C(=O)N(CC#C)C(=O)C=2N(CC#CC)C=1N1CCNCC1 VVNHSWZPXMZLEF-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- RYIGNEOBDRVTHA-UHFFFAOYSA-N 8-chlorotheophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2 RYIGNEOBDRVTHA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 240000005636 Dryobalanops aromatica Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical group N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000006859 Swern oxidation reaction Methods 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- UICVVNQQOOFSFC-UHFFFAOYSA-N [7-(2-chlorophenyl)-1-methyl-2,6-dioxopurin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound C1=2C(=O)N(C)C(=O)N(COC(=O)C(C)(C)C)C=2N=CN1C1=CC=CC=C1Cl UICVVNQQOOFSFC-UHFFFAOYSA-N 0.000 description 1
- JDROIDDVFKBPNK-UHFFFAOYSA-N [8-chloro-7-(2-chlorophenyl)-1-methyl-2,6-dioxopurin-3-yl]methyl 2,2-dimethylpropanoate Chemical compound C1=2C(=O)N(C)C(=O)N(COC(=O)C(C)(C)C)C=2N=C(Cl)N1C1=CC=CC=C1Cl JDROIDDVFKBPNK-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- GLRAHDCHUZLKKC-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid;hydrate Chemical compound O.CC#N.OC(=O)C(F)(F)F GLRAHDCHUZLKKC-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical group C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- BMBANPOHPFKVTA-UHFFFAOYSA-N benzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NC(=O)C1=CC=CC=C1 BMBANPOHPFKVTA-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- PFYXSUNOLOJMDX-UHFFFAOYSA-N bis(2,5-dioxopyrrolidin-1-yl) carbonate Chemical compound O=C1CCC(=O)N1OC(=O)ON1C(=O)CCC1=O PFYXSUNOLOJMDX-UHFFFAOYSA-N 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960004111 buformin Drugs 0.000 description 1
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 description 1
- NEEDEQSZOUAJMU-UHFFFAOYSA-N but-2-yn-1-ol Chemical compound CC#CCO NEEDEQSZOUAJMU-UHFFFAOYSA-N 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- LADPCMZCENPFGV-UHFFFAOYSA-N chloromethoxymethylbenzene Chemical compound ClCOCC1=CC=CC=C1 LADPCMZCENPFGV-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical group C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- JIDMEYQIXXJQCC-UHFFFAOYSA-L copper;2,2,2-trifluoroacetate Chemical compound [Cu+2].[O-]C(=O)C(F)(F)F.[O-]C(=O)C(F)(F)F JIDMEYQIXXJQCC-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- KFGVRWGDTLZAAO-UHFFFAOYSA-N cyclopenta-1,3-diene dicyclohexyl(cyclopenta-1,3-dien-1-yl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.C1CCC(CC1)P(C1CCCCC1)c1ccc[cH-]1 KFGVRWGDTLZAAO-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- FQXWJZJFIXNGTC-UHFFFAOYSA-N ethyl 1-(7-butan-2-yl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)oxycyclopropane-1-carboxylate Chemical compound N=1C=2N=C(N3CCNCC3)N(C(C)CC)C=2C(=O)N(C)C=1OC1(C(=O)OCC)CC1 FQXWJZJFIXNGTC-UHFFFAOYSA-N 0.000 description 1
- DPMGQZGXWRHYPE-UHFFFAOYSA-N ethyl 1-hydroxycyclopropane-1-carboxylate Chemical compound CCOC(=O)C1(O)CC1 DPMGQZGXWRHYPE-UHFFFAOYSA-N 0.000 description 1
- KTLJNFXYJFBYKC-UHFFFAOYSA-N ethyl 2-(7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)oxypropanoate Chemical compound CC#CCN1C=2C(=O)N(C)C(OC(C)C(=O)OCC)=NC=2N=C1N1CCNCC1 KTLJNFXYJFBYKC-UHFFFAOYSA-N 0.000 description 1
- ARFLASKVLJTEJD-UHFFFAOYSA-N ethyl 2-bromopropanoate Chemical compound CCOC(=O)C(C)Br ARFLASKVLJTEJD-UHFFFAOYSA-N 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- XIWBSOUNZWSFKU-UHFFFAOYSA-N ethyl piperidine-3-carboxylate Chemical compound CCOC(=O)C1CCCNC1 XIWBSOUNZWSFKU-UHFFFAOYSA-N 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- IZZWJPQHPPRVLP-UHFFFAOYSA-N hexane;2-methoxy-2-methylpropane Chemical compound CCCCCC.COC(C)(C)C IZZWJPQHPPRVLP-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- IYUKFAFDFHZKPI-UHFFFAOYSA-N hydron;methyl 2-aminopropanoate;chloride Chemical compound Cl.COC(=O)C(C)N IYUKFAFDFHZKPI-UHFFFAOYSA-N 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 125000003564 m-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(C#N)=C1[H])C([H])([H])* 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- XDBOBNVQEBSKFO-UHFFFAOYSA-N magnesium;di(propan-2-yl)azanide Chemical compound CC(C)N(C(C)C)[Mg]N(C(C)C)C(C)C XDBOBNVQEBSKFO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- RRGSLLGXXJHFJU-UHFFFAOYSA-N methyl 2-(7-but-2-ynyl-1-methyl-6-oxo-8-piperazin-1-ylpurin-2-yl)sulfanylacetate 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC#CCN1C=2C(=O)N(C)C(SCC(=O)OC)=NC=2N=C1N1CCNCC1 RRGSLLGXXJHFJU-UHFFFAOYSA-N 0.000 description 1
- NVVCICUNZCORLH-UHFFFAOYSA-N methyl 2-(7-but-2-ynyl-3-methyl-2,6-dioxo-8-piperazin-1-ylpurin-1-yl)acetate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC#CCN1C=2C(=O)N(CC(=O)OC)C(=O)N(C)C=2N=C1N1CCNCC1 NVVCICUNZCORLH-UHFFFAOYSA-N 0.000 description 1
- LUPGWIZWCSJKOU-UHFFFAOYSA-N methyl 2-[7-but-2-ynyl-6-oxo-1-(2-phenylethyl)-8-piperazin-1-ylpurin-2-yl]sulfanylacetate;hydrochloride Chemical compound Cl.CC#CCN1C=2C(=O)N(CCC=3C=CC=CC=3)C(SCC(=O)OC)=NC=2N=C1N1CCNCC1 LUPGWIZWCSJKOU-UHFFFAOYSA-N 0.000 description 1
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical compound COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 125000005322 morpholin-1-yl group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000006505 p-cyanobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C#N)C([H])([H])* 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- KDLHZDBZIXYQEI-VENIDDJXSA-N palladium-100 Chemical compound [100Pd] KDLHZDBZIXYQEI-VENIDDJXSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000004714 phosphonium salts Chemical class 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical group C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000004304 potassium nitrite Substances 0.000 description 1
- 235000010289 potassium nitrite Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical group N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- JQLWSRMYBDXVRV-UHFFFAOYSA-N pyridazin-4-one Chemical compound O=C1C=CN=N[CH]1 JQLWSRMYBDXVRV-UHFFFAOYSA-N 0.000 description 1
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical group C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- XJJBXZIKXFOMLP-ZETCQYMHSA-N tert-butyl (2s)-pyrrolidine-2-carboxylate Chemical compound CC(C)(C)OC(=O)[C@@H]1CCCN1 XJJBXZIKXFOMLP-ZETCQYMHSA-N 0.000 description 1
- YKUAVPQMXBRSGH-UHFFFAOYSA-N tert-butyl 4-(1-but-2-ynyl-4-cyano-5-ethoxycarbonylimidazol-2-yl)piperazine-1-carboxylate Chemical compound CC#CCN1C(C(=O)OCC)=C(C#N)N=C1N1CCN(C(=O)OC(C)(C)C)CC1 YKUAVPQMXBRSGH-UHFFFAOYSA-N 0.000 description 1
- WBTYVKHIAIZSGB-UHFFFAOYSA-N tert-butyl 4-(1-but-2-ynyl-4-formyl-5-methoxycarbonylimidazol-2-yl)piperazine-1-carboxylate Chemical compound CC#CCN1C(C(=O)OC)=C(C=O)N=C1N1CCN(C(=O)OC(C)(C)C)CC1 WBTYVKHIAIZSGB-UHFFFAOYSA-N 0.000 description 1
- SMONSZFMKJYHDF-UHFFFAOYSA-N tert-butyl 4-(7-but-2-ynyl-2-cyano-1-methyl-6-oxopurin-8-yl)piperazine-1-carboxylate Chemical compound N=1C=2N=C(C#N)N(C)C(=O)C=2N(CC#CC)C=1N1CCN(C(=O)OC(C)(C)C)CC1 SMONSZFMKJYHDF-UHFFFAOYSA-N 0.000 description 1
- PZESBAFKWRTHJL-UHFFFAOYSA-N tert-butyl 4-[7-(2-chlorophenyl)-2-(2-ethoxy-2-oxoethoxy)-1-methyl-6-oxopurin-8-yl]piperazine-1-carboxylate Chemical compound C=1C=CC=C(Cl)C=1N1C=2C(=O)N(C)C(OCC(=O)OCC)=NC=2N=C1N1CCN(C(=O)OC(C)(C)C)CC1 PZESBAFKWRTHJL-UHFFFAOYSA-N 0.000 description 1
- SDSSWNLMDGLAPA-UHFFFAOYSA-N tert-butyl N-[1-(5-methyl-4-oxo-1H-imidazo[4,5-d]pyridazin-2-yl)piperidin-3-yl]carbamate Chemical compound N1C=2C(=O)N(C)N=CC=2N=C1N1CCCC(NC(=O)OC(C)(C)C)C1 SDSSWNLMDGLAPA-UHFFFAOYSA-N 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- SUEUEIYVVKDJMK-UHFFFAOYSA-N tert-butyl n-[1-[7-but-2-ynyl-2-cyano-1-[(2-cyanophenyl)methyl]-6-oxopurin-8-yl]piperidin-3-yl]carbamate Chemical compound O=C1C=2N(CC#CC)C(N3CC(CCC3)NC(=O)OC(C)(C)C)=NC=2N=C(C#N)N1CC1=CC=CC=C1C#N SUEUEIYVVKDJMK-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003527 tetrahydropyrans Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- ONCNIMLKGZSAJT-UHFFFAOYSA-N thieno[3,2-b]furan Chemical group S1C=CC2=C1C=CO2 ONCNIMLKGZSAJT-UHFFFAOYSA-N 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- NMLXKNNXODLJIN-UHFFFAOYSA-M zinc;carbanide;chloride Chemical compound [CH3-].[Zn+]Cl NMLXKNNXODLJIN-UHFFFAOYSA-M 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Definitions
- the present invention relates to pharmaceutical agents comprising a dipeptidyl peptidase IV (DPPIV) inhibitor and a biguanide agent, which enhance the effects of active circulating glucagon-like peptide-1 (GLP-1) and/or active circulating glucagon-like peptide-2 (GLP-2).
- DPPIV dipeptidyl peptidase IV
- GLP-1 active circulating glucagon-like peptide-1
- GLP-2 active circulating glucagon-like peptide-2
- Glucagon-like peptide-1 (GLP-1) is a hormone known to be secreted in response to food intake from L cells in the distal part of the small intestine. It enhances the secretion of insulin from pancreatic ⁇ cells in a glucose-dependent manner. GLP-1 is degraded and rapidly inactivated by dipeptidyl peptidase IV (DPPIV).
- DPPIV inhibitors can be used as preventive and/or therapeutic agents for diseases such as diabetes (particularly typeII diabetes) and obesity, with which GLP-1 levels are associated. DPPIV inhibitors have been under development in clinical trials and are disclosed in Patent documents 1, 2, and 3.
- Metformin a biguanide agent, has commonly been used as a preventive and/or therapeutic agent for diabetes.
- GLP-1 levels are increased in obese non-diabetic patients upon administration of metformin (Non-patent document 1); and a combination of metformin arid GLP-1 is effective to treat typeII diabetes (Non-patent document 2).
- a combination of metformin arid GLP-1 is effective to treat typeII diabetes (Non-patent document 2).
- the level of GLP-1 is elevated transiently by metformin, GLP-1 is rapidly degraded and inactivated by DPPIV as described above. Therefore, the elevated level of GLP-1 does not have a long duration and thus GLP-1 effects are extremely reduced. This is a problem to be solved.
- Non-patent documents 3 and 4 suggest the applicability of the combined use of a DPPIV inhibitor and metformin.
- Patent documents 4 to 8 describe the combined use of a DPPIV inhibitor and a biguanide agent. However, these documents have not disclosed particular test results for the combined use of these agents. In other words, there is no combination drug that contains a DPPIV inhibitor and metformin, which is known to enhance the effects of GLP-1.
- GLP-2 glucagon-like peptide-2
- GLP-1 glucagon-like peptide-2
- DPPIV distal part of the small intestine
- GLP-2 is rapidly degraded and inactivated by DPPIV. Consequently, there has been demand to develop agents suppressing the degradation of GLP-2, and therefore enhancing GLP-2 effects.
- GLP-2 levels upon administration of metformin or the enhancement of GLP-2 effects by the combined use of a DPPIV inhibitor and metformin.
- An objective of the present invention is to provide pharmaceutical agents that enhance the pharmacological actions of active circulating GLP-1 and/or active circulating GLP-2, by suppressing the degradation of GLP-1 and/or GLP-2 when levels have been elevated by a biguanide agent.
- the present inventors conducted extensive studies in view of the above background, and revealed that the combined use of a DPPIV inhibitor and a biguanide agent enhanced the pharmacological actions of active circulating GLP-1 and/or active circulating GLP-2. This is because the DPPIV inhibitor suppresses the degradation of active circulating GLP-1 and/or active circulating GLP-2, when levels are increased by the biguanide agent. Thus, the inventors completed the present invention.
- the present invention provides:
- ⁇ 1>a pharmaceutical agent comprising a dipeptidyl peptidase IV inhibitor and a biguanide agent in combination;
- the pharmaceutical agent according to ⁇ 1>or ⁇ 4> wherein the dipeptidyl peptidase IV inhibitor is any one compound selected from:
- isoleucine thiazolidide isoleucine pyrrolidide; and valine pyrrolidide;
- the pharmaceutical agent according to ⁇ 1>or ⁇ 4> wherein the dipeptidyl peptidase IV inhibitor is a compound represented by the following formula, or a salt or hydrate thereof,
- T 1 is a piperazin-1-yl group or a 3-amino-piperidin-1-yl group
- T 1 is a piperazin-1-yl group
- R 1 is either a methyl group, a cyanobenzyl group, a fluorocyanobenzyl group, a phenethyl group, a 2-methoxyethyl group, or a 4-methoxycarbonylpridin-2-yl group;
- R 2 is either a hydrogen atom, a cyano group, a methoxy group, a carbamoylphenyloxy group, or a group represented by the formula:
- the pharmaceutical agent according to ⁇ 1>or ⁇ 4> wherein the dipeptidyl peptidase IV inhibitor is a compound represented by the following formula, or a salt or hydrate thereof,
- T 1 is a piperazin-1-yl group
- X is a 2-butynyl group or a 2-chlorophenyl group
- R 1 is a hydrogen atom, a methyl group, a 2-propynyl group, a 2-butynyl group, a cyanomethyl group, a phenethyl group, a phenoxyethyl group, or a group represented by the formula:
- R 3 represents a hydroxyl group, a C 1-6 alkoxy group, or a phenyl group
- R 2 is a hydrogen atom, a C 1-6 alkyl group, an ethoxyethyl group, a tetrahydrofuranylmethyl group, or a group represented by the formula:
- the pharmaceutical agent according to ⁇ 1>or ⁇ 2> which is a preventive or therapeutic agent for a disease which is associated with active circulating GLP-1 and/or active circulating GLP-2;
- the pharmaceutical agent according to ⁇ 27> wherein the disease is at least any one selected from the group consisting of: diabetes, obesity, hyperlipidemia, and gastrointestinal diseases;
- the pharmaceutical agent according to ⁇ 29> wherein the disease is a gastrointestinal disease
- ⁇ 31> a method for preventing or treating a disease which is associated with active circulating GLP-1 and/or active circulating GLP-2, which comprises administering the pharmaceutical agent according to ⁇ 1>or ⁇ 2>at an effective amount;
- ⁇ 33> a method for preventing or treating a disease which is associated with active circulating GLP-2, which comprises administering the pharmaceutical agent according to ⁇ 3>or ⁇ 4>at an effective amount;
- ⁇ 35> a method for enhancing the effects of active circulating GLP-1 and/or active circulating GLP-2, which comprises using the pharmaceutical agent according to ⁇ 1>or ⁇ 2>;
- ⁇ 36> a method for enhancing the effects of active circulating GLP-2, which comprises using the pharmaceutical agent according to ⁇ 3>or ⁇ 4>.
- the present invention also includes:
- GLP-2 active circulating glucagon-like peptide-2
- GLP-2 active circulating glucagon-like peptide-2
- GLP-2 active circulating glucagon-like peptide-2
- GLP-1 active circulating glucagon-like peptide-1
- the dipeptidyl peptidase IV inhibitor is as defined by any one of ⁇ 5>to ⁇ 25>listed above and the biguanide agent is as defined above in ⁇ 26>.
- a structural formula of a compound sometimes represents a certain isomer for convenience of description.
- compounds of the present invention may include all possible isomers, such as structurally possible geometric isomers, optical isomers generated due to the presence of asymmetric carbons, stereoisomers, tautomers, and mixtures of isomers, and are not limited to formulae being used for the convenience of description, and may be either of two isomers or a mixture of both isomers.
- compounds of the present invention may be either optically active compounds having an asymmetric carbon atom in their molecules or their racemates, and are not restricted to either of them but include both.
- compounds of the present invention may exhibit crystalline polymorphism, but likewise are not restricted to any one of these but may be in any one of these crystal forms or exist as a mixture of two or more crystal forms.
- Compounds of the present invention also include both anhydrous and hydrated forms. Substances produced through in vivo metabolism of compounds of the invention are also within the scope of claims.
- C 1-6 alkyl group refers to a linear or branched alkyl group containing 1 to 6 carbon atoms, which is a monovalent group obtained by removal of any one of the hydrogen atoms from an aliphatic hydrocarbon containing 1 to 6 carbons, and specifically, includes, for example, a methyl group, an ethyl group, a 1-propyl group, a 2-propyl group, a 2-methyl-1-propyl group, a 2-methyl-2-propyl group, a 1-butyl group, a 2-butyl group, a 1-pentyl group, a 2-pentyl group, a 3-pentyl group, a 2-methyl-1-butyl group, a 3-methyl-1-butyl group, a 2-methyl-2-butyl group, a 3-methyl-2-butyl group, a 2,2-dimethyl-1-propyl group, a 1-hexyl group, a 2-hexyl group,
- C 2-6 alkenyl group refers to a linear or branched alkenyl group containing 2 to 6 carbons, and specifically includes, for example, a vinyl group, an allyl group, a 1-propenyl group, a 2-propenyl group, a 1-butenyl group, a 2-butenyl group, a 3-butenyl group, a pentenyl group, and a hexenyl group.
- C 2-6 alkynyl group refers to a linear or branched alkynyl group containing 2 to 6 carbons, and specifically includes, for example, an ethynyl group, a 1-propynyl group, a 2-propynyl group, a butynyl group, a pentynyl group, and a hexynyl group.
- C 3-8 cycloalkyl group refers to a cyclic aliphatic hydrocarbon group containing 3 to 8 carbon atoms, and specifically includes, for example, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, and a cyclooctyl group.
- C 1-6 alkylene group refers to a divalent group obtained by removal of another arbitrary hydrogen atom from a “C 1-6 alkyl group” defined above, and specifically includes, for example, a methylene group, a 1,2-ethylene group, a 1,1-ethylene group, a 1,3-propylene group, a tetramethylene group, a pentamethylene group, and a hexamethylene group.
- C 3-8 cycloalkylene group refers to a divalent group obtained by removal of another arbitrary hydrogen atom from a “C 3-8 cycloalkyl group” defined above.
- C 1-6 alkoxy group refers to an oxy group linked to a “C 1-6 alkyl group” defined above, and specifically includes, for example, a methoxy group, an ethoxy group, a 1-propyloxy group, a 2-propyloxy group, a 2-methyl-1-propyloxy group, a 2-methyl-2-propyloxy group, a 1-butyloxy group, a 2-butyloxy group, a 1-pentyloxy group, a 2-pentyloxy group, a 3-pentyloxy group, a 2-methyl-1-butyloxy group, a 3-methyl-1-butyloxy group, a 2-methyl-2-butyloxy group, a 3-methyl-2-butyloxy group, a 2,2-dimethyl-1-propyloxy group, a 1-hexyloxy group, a 2-hexyloxy group, a 3-hexyloxy group, a 2-methyl-1-pentyloxy group, a 2-methyl-1-p
- C 1-6 alkylthio group refers to a thio group linked to a “C 1-6 alkyl group” defined above, and specifically includes, for example, a methylthio group, an ethylthio group, a 1-propylthio group, a 2-propylthio group, a butylthio group, and a pentylthio group.
- C 2-7 alkoxycarbonyl group refers to a carbonyl group linked to a “C 1-6 alkoxy group” defined above, and specifically includes, for example, a methoxycarbonyl group, an ethoxycarbonyl group, a 1-propyloxycarbonyl group, and a 2-propyloxycarbonyl group.
- C 2-7 alkylcarbonyl group refers to a carbonyl group linked to a “C 1-6 alkyl group” defined above, and specifically includes, for example, a methylcarbonyl group, an ethylcarbonyl group, a 1-propylcarbonyl group, and a 2-propylcarbonyl group.
- halogen atom refers to a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
- C 6-10 aryl group refers to an aromatic cyclic hydrocarbon group containing 6 to 10 carbon atoms, and specifically includes, for example, a phenyl group, a 1-naphthyl group, and a 2-naphthyl group.
- heteroatom refers to a sulfur atom, an oxygen atom, or a nitrogen atom.
- the phrase “5 to 10-membered heteroaryl ring” refers to an aromatic 5 to 10-membered ring containing one or more heteroatoms, and specifically includes, for example, a pyridine ring, a thiophene ring, a furan ring, a pyrrole ring, an oxazole ring, an isoxazole ring, a thiazole ring, a thiadiazole ring, an isothiazole ring, an imidazole ring, a triazole ring, a pyrazole ring, a furazan ring, a thiadiazole ring, an oxadiazole ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, a triazine ring, indole ring, an isoindole ring, an indazole ring, a chromene ring,
- Preferable “5 to 10-membered heteroaryl rings” include a pyridine ring, a thiophene ring, a furan ring, a pyrrole ring, an imidazole ring, a 1,2,4-triazole ring, a thiazole ring, a thiadiazole ring, a pyrazole ring, a furazan ring, a thiadiazole ring, a pyridazine ring, a pyrimidine ring, a pyrazine ring, an isoquinoline ring, a benzoxazole ring, a benzothiazole ring, and a benzimidazole ring.
- the most preferable example is a pyridine ring.
- the phrase “5 to 10-membered heteroaryl group” refers to a monovalent or divalent group obtained by removal of any one or two hydrogen atoms from a “5 to 10-membered heteroaryl ring” described above.
- the atoms constituting the ring include 1 to 2 heteroatoms
- the ring may contain 1 to 2 double bonds
- the ring may contain 1 to 3 carbonyl groups
- the 4 to 8-membered heterocyclic ring includes, for example, an azetidine ring, a pyrrolidine ring, a piperidine ring, an azepan ring, an azocane ring, a tetrahydrofuran ring, a tetrahydropyran ring, a morpholine ring, a thiomorpholine ring, a piperazine ring, a thiazolidine ring, a dioxane ring, an imidazoline ring, a thiazoline ring, and a ring represented by one of the formulae: (where s represents an integer from 1 to 3; T 3x represents a methylene group, an oxygen atom or a group represented by the formula —NT 4x -, wherein T 4x represents a hydrogen atom or C 1-6 alkyl group.
- the “4- to 8-membered heterocyclic rings” include a pyrrolidine ring, a piperidine ring, an azepan ring, a morpholine ring, a thiomorpholine ring, a piperazine ring, a dihydrofuran-2-one ring, and a thiazolidine ring.
- the phrase “4 to 8-membered heterocyclic group” refers to a monovalent or divalent group obtained by removal of any one or two hydrogen atoms from a “4 to 8-membered heterocycle” described above.
- the “4 to 8-membered heterocyclic groups” include a piperidin-1-yl group, a pyrrolidin-1-yl group, and a morpholin-4-yl group.
- C 6-10 aryl C 1-6 alkyl group refers to a group obtained by substitution of a “C 6-10 aryl group” defined above for an arbitrary hydrogen atom in a “C 1-6 alkyl group” defined above, and specifically includes, for example, a benzyl group, a phenethyl group, and a 3-phenyl-1-propyl group.
- the phrase “5 to 10-membered heteroaryl C 1-6 alkyl group” refers to a group obtained by substitution of a “5 to 10-membered heteroaryl group” defined above for an arbitrary hydrogen atom in a “C 1-6 alkyl group” defined above, and specifically, includes for example, a 2-pyridylmethyl and a 2-thienylmethyl group.
- the phrase “4 to 8-membered heterocyclic C 1-6 alkyl group” refers to a group obtained by substitution of a “4 to 8-membered heterocyclic group” defined above for an arbitrary hydrogen atom in a “C 1-6 alkyl group” defined above.
- the phrase “monocyclic or bicyclic 4 to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, that may have one or more substituents” refers to a non-aromatic cyclic group which may have one or more substituents.
- the non-aromatic cyclic groups :
- the atoms constituting the ring of the cyclic group include one or two nitrogen atoms;
- the group is a monocyclic or bicyclic structure.
- the group is represented by the formula: (where n and m each independently represent 0 or 1; R 31 to R 44 independently represent a hydrogen atom or a substituent selected from substituents referred to in the phrase “which may have one or more substituents” (the substituent group S defined below); any two of R 31 to R 44 may in combination form a C 1-6 alkylene group).
- substituents means that a group may have one or more substituents in any combination at replaceable positions.
- substituents include, for example, a substituent selected from the substituent group S defined below.
- This group consists of:
- This group consists of: hydroxyl, cyano, a halogen atom, C 1-6 alkyl, C 3-8 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, phenyl, 1-naphthyl, 2-naphthyl, 5 to 10-membered heteroaryl, 4 to 8-membered heterocyclic ring, C 1-6 alkoxy, C 1-6 alkylthio, C 2-7 alkoxycarbonyl group, etc.
- the ⁇ substituent group S> preferably consists of:
- C 1-6 alkyl group which may have one or more substituents in the substituent group B defined above refers to a “C 1-6 alkyl group” which may have one or more groups selected from the substituents referred to in the phrase “which may have one or more substituents” at replaceable positions.
- the “C 1-6 alkyl group which may have one or more substituents” refers to a C 1-6 alkyl group which may have one or two substituents selected from the group consisting of a cyano group, a carboxyl group, a C 2- ⁇ alkoxycarbonyl group, a group represented by the formula —NR 3T COR 4T , a group represented by the formula —CONR 3T R 4T (where R 3T and R 4T each independently represent a hydrogen atom or a C 1-6 alkyl group), and a C 1-6 alkoxy group.
- the phrase “when Z 2 represents a group of the formula —CR 2 ⁇ , R 1 , and R 2 may in combination form a 5 to 7-membered ring” means that compounds represented by formula (I) indicated above includes compounds (III) represented by the formula: (where Z 1 , X, and T 1 are as defined above; A T1 represents an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, a carbonyl group, a methylene group which may have one or more substituents, or a nitrogen atom which may have one or more substituents; A T2 represents a C 2-6 alkylene group which may have one or more substituents). In formula (III) shown above, A T1 preferably represents an oxygen atom, and A T2 preferably represents a C 2-4 alkylene group.
- cyanobenzyl group refers to a benzyl group having one cyano group, and specifically, includes, for example, a 2-cyanobenzyl group, a 3-cyanobenzyl group, and a 4-cyanobenzyl group.
- fluorocyanobenzyl group refers to a benzyl group having one fluorine atom and one cyano group, and specifically, includes, for example, a 2-cyano-4-fluorobenzyl group and a 2-cyano-6-fluorobenzyl group.
- carbamoylphenyloxy group refers to a phenyloxy group having a group represented by the formula —CONH 2 , and specifically, includes, for example, a 2-carbamoylphenyloxy group, a 3-carbamoylphenyloxy group, and a 4-carbamoylphenyloxy group.
- salts include, for example, inorganic acid salts, organic acid salts, inorganic base salts, organic base salts, and acidic or basic amino acid salts.
- Examples of preferred inorganic acid salts include hydrochloride, hydrobromide, sulfate, nitrate, and phosphate.
- Examples of preferred organic salts include acetate, succinate, fumarate, maleate, tartrate, citrate, lactate, stearate, benzoate, methanesulfonate, and p-toluene sulfonate.
- Examples of preferred inorganic base salts include: alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; aluminum salts; and ammonium salts.
- Examples of preferred organic base salts include diethylamine salts, diethanolamine salts, meglumine salts, and N,N′-dibenzylethylenediamine salts.
- Examples of preferred acidic amino acid salts include aspartate and glutamate.
- Examples of preferred basic amino acid salts include arginine salts, lysine salts, and ornithine salts.
- the phrase “enhancing the effects of active circulating GLP-1 and/or active circulating GLP-2” means that the effects of active circulating GLP-1 and/or active circulating GLP-2 are enhanced due to increased blood levels of these peptides, which results from their enhanced secretion or suppressed degradation.
- the phrase “enhancing the effects of active circulating GLP-2” means that the effects of active circulating GLP-2 are enhanced due to the increased blood level of this peptide, which results from its enhanced secretion or suppressed degradation.
- the effects of active circulating GLP-1 include: enhancing secretion of insulin in a glucose-dependent manner; enhancing biosynthesis of insulin; suppressing secretion of glucagon; promoting ⁇ cell renewal; activating glycogen synthase in the liver; suppressing food intake; suppressing weight gain; suppressing gastric emptying; and suppressing gastric acid secretion.
- the effects of active circulating GLP-2 include: promoting growth of intestinal epithelial cells; promoting growth of epithelial cells in the gastrointestinal tract; suppressing apoptosis of epithelial cells in the gastrointestinal tract; maintaining the gastrointestinal barrier function; enhancing glucose absorption; suppressing secretion of gastric acid; and enhancing blood flow in the gastrointestinal tract.
- enhancing the effect(s) means enhancing the effects described above.
- the “biguanide agent” refers, for example, to phenformin, metformin, and buformin, which are agents that have the following effects: suppressing gluconeogenesis and glycogenolysis in the liver; potentiating the susceptibility of skeletal muscle to insulin; suppressing glucose absorption in the intestinal tract; and decreasing weight by suppressing food intake.
- a preferred biguanide agent is metformin.
- the “disease which is associated with active circulating GLP-1 and/or active circulating GLP-2” include, for example, diabetes, obesity, hyperlipidemia, hypertension, arteriosclerosis, and gastrointestinal diseases.
- the “disease which is associated with active circulating GLP-2” includes, for example, gastrointestinal diseases.
- Isoleucine thiazolidide, isoleucine pyrrolidide, and valine pyrrolidide can be produced according to the method described in U.S. Pat. No. 6,548,481.
- the compound represented by formula (II) indicated herein can be produced by the method described below in [Typical synthesis methods] or any one of the methods described in U.S. Patent Application Publication No. 2002/0161001; U.S. Patent Application Publication No. 2003/0105077; and U.S. Patent Application Publication No. 2002/0198205.
- R 31 to R 42 , n, m, R 1 , R 2 , X, A 0 , A 1 , A 2 , R A , and T 1 are the same as defined above.
- U 1 , U 3 and Hal each independently represent a leaving group such as a chlorine atom, a bromine atom, an iodine atom, a methanesulfonyloxy group, or a p-toluenesulfonyloxy group.
- R p1 , R p2 , and R p3 each independently represent an —NH-protecting group such as a pivalyloxymethyl group and a trimethylsilylethoxymethyl group.
- R p4 represents a hydroxyl group-protecting group such as a t-butyldimethylsilyl group and a t-butyldiphenylsilyl group.
- R p5 represents an NH-protecting group such as N,N-dimethylsulfamoyl, trityl, benzyl, and t-butoxycarbonyl.
- U 2 and U 4 each independently represent a chlorine atom, a bromine atom, an iodine atom, a methanesulfonyloxy group, a p-toluenesulfonyloxy group, a group represented by the formula —B(OH) 2 , a 4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl group, or a group represented by the formula —Sn(R z ) 3 (where R z represents a C 1-6 alkyl group).
- R x2 is a group represented by the formula —O-A 2 , a group represented by the formula —S-A 2 , a group represented by the formula —N(R A )A 2 , or a 4- to 8-membered heterocyclic group which may have one or more substituents (for example, 1-pyrrolidinyl, 1-morpholinyl, 1-piperazinyl, or 1-piperidyl), etc.
- R x3 represents a group of the formula -A 0 -A 1 -A 2 , such as a cyano group, a C 1-6 alkyl group which may have one or more substituents, a C 3-8 cycloalkyl group which may have one or more substituents, a C 2-6 alkenyl group which may have one or more substituents, a C 2-6 alkynyl group which may have one or more substituents, and a C 6-10 aryl group which may have one or more substituents.
- a 2COOR represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group, each of which contains an ester group.
- a 2COOH represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 akynyl group, C 6-10 aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group, each of which contains a carboxylic acid.
- a 2NO2 represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group, each of which contains a nitro group.
- a 2NH2 represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group, each of which contains an amino group.
- a 2CN represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, a C 6-10 aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group, each of which contains a nitrile group.
- a CONH2 represents a C 1-6 alkyl group, a C 3-8 cycloalkyl group, a C 2-6 alkenyl group, a C 2-6 alkynyl group, C 6-10 aryl group, a 5- to 10-membered heteroaryl group, a 4- to 8-membered heterocyclic group, a 5- to 10-membered heteroaryl C 1-6 alkyl group, or a C 6-10 aryl C 1-6 alkyl group, each of which contains a carboxylic amide group.
- M represents —MgCl, —MgBr, —Sn(R z ) 3 (where R z is as defined above), etc.
- room temperature refers to a temperature of about 20 to about 30° C.
- T 1a is defined as the group represented by T 1 , or represents a group of the formula: a group represented by the formula: (where R 31 to R 44 are as defined above, except that any one of R 31 to R 44 represents —NH—R p3 ), or a group represented by the formula: (where R 31 to R 44 are as defined above, except that any one of R 31 to R 40 represents —NH—R p3 ).
- s 1 to 4.
- R 51 to R 54 each independently represent a hydrogen atom, a C 1-6 alkyl group, or a C 6-10 aryl group.
- an —NH-protecting reagent is reacted with compound (1a) [CAS No. 56160-64-6] to give compound (2a).
- the reaction conditions are selected depending on the type of —NH-protecting reagent to be used.
- the reaction may be performed under conditions that are generally used to introduce a protecting group using the reagent.
- An —NH-protecting reagent can be a reagent that is generally used to introduce an —NH-protecting group.
- —NH-protecting reagents include, for example, chloromethyl pivalate. It is preferable to use 1 to 2 equivalents of a protecting reagent.
- Solvents for the reaction include acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, and dimethoxyethane. N,N-dimethylformamide is preferably used.
- the reaction can be achieved in the presence of a base.
- bases to be used in the reaction include cesium carbonate, lithium carbonate, sodium carbonate, potassium carbonate, and sodium hydride.
- Sodium hydride is preferably used.
- a base is preferably used in an amount of 1 to 5 equivalents.
- the reaction can be conducted at a temperature ranging from 0° C. to 150° C. A preferred reaction temperature is room temperature.
- Compound (2a-2) can be any compound that is an electrophilic reagent such as an alkyl halide.
- an electrophilic reagent such as an alkyl halide.
- alkyl halides such as iodomethane, iodoethane, iodopropane, and benzyl bromide
- alkenyl halides such as allyl bromide and 1-bromo-3-methyl-2-butene
- alkynyl halides such as propargyl bromide and 1-bromo-2-butyne.
- One to two equivalents of an electrophilic reagent are preferably used.
- Solvents for the reaction include, for example, dimethyl sulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, and toluene.
- the reaction can be achieved in the presence or absence of a base.
- bases to be used in the reaction include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium hydride, sodium hydride, potassium hydride, butyllithium, methyllithium, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, and potassium bis(trimethylsilyl)amide.
- one to two equivalents of a base are preferably used.
- the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
- compound (4a) can be prepared from compound (3a), for example, by catalytic reduction under a hydrogen atmosphere in the presence of a metal catalyst, but the reaction conditions are not limited thereto.
- Specific solvents for the reaction include, for example, methanol, ethanol, propanol, acetic acid, dimethyl sulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, and toluene.
- metal catalysts include palladium carbon, platinum oxide, and Raney nickel. A metal catalyst is preferably used at 0.5 to 50 weight %. A preferred hydrogen pressure is 1 to 5 atm.
- the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
- compound (4a-2) are: alkyl halides such as iodomethane, iodoethane, iodopropane, and benzyl bromide; alkenyl halides such as allyl bromide and 1-bromo-3-methyl-2-butene; or alkyl halides such as propargyl bromide and 1-bromo-2-butyne. These halides are preferably used in an amount of one to two equivalents.
- Solvents for the reaction include dimethyl sulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, and toluene.
- the reaction can be carried out in the presence or absence of a base.
- bases to be used in the reaction include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium hydride, sodium hydride, potassium hydride, butyllithium, methyllithium, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, and potassium bis(trimethylsilyl)amide.
- 1 to 4 equivalents of a base are preferably used.
- the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
- Compound (5a) can be obtained by reacting compound (4a) with compound (4a-2) in the presence of a copper catalyst and a base. In this case, it is preferable to use 0.1 to 2 equivalents of a copper catalyst and 1 to 10 equivalents of a base.
- compound (4a-2) may be arylboronic acid, heteroarylboronic acid, or such, in which X is a C 6-10 aryl group which may have one or more substituents or a 5- to 10-membered heteroaryl group which may have one or more substituents, and U 2 is —B(OH) 2 or such.
- X is a C 6-10 aryl group which may have one or more substituents or a 5- to 10-membered heteroaryl group which may have one or more substituents
- U 2 is —B(OH) 2 or such.
- One to three equivalents of compound (4a-2) are preferably used.
- reaction solvents include dichloromethane, chloroform, 1,4-dioxane, tetrahydrofuran, toluene, pyridine, N,N-dimethylformamide, and N-methylpyrrolidone.
- Bases include triethylamine, diisopropylethylamine, pyridine, and N,N-dimethylaminopyridine.
- Copper catalysts include copper (II) acetate, copper (II) trifluoroacetate, copper (II) chloride, and copper (II) iodide. The reaction can be conducted at a temperature ranging from 0° C. to 150° C.
- compound (5a) is reacted with a halogenating agent to give compound (6a).
- halogenating agents include, for example, N-chlorosuccinimide, N-bromosuccinimide, and N-iodosuccinimide.
- a halogenating agent is preferably used in an amount of 1 to 4 equivalents.
- Solvents for the reaction include acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, and dimethoxyethane.
- the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
- compound (6a) is reacted with compound (7a) to give compound (8a).
- compound (8a) 1 to 4 equivalents of compound (7a) are preferably used.
- the reaction can be carried out, for example, in a solvent such as tetrahydrofuran, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, methanol, ethanol, 1,4-dioxane, toluene, and xylene, or in the absence of a solvent.
- a solvent such as tetrahydrofuran, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, methanol, ethanol, 1,4-dioxane, toluene, and xylene
- a solvent such as tetrahydrofuran, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, methanol, ethanol, 1,4-dioxane, toluene, and xylene
- the reaction can be conducted at a temperature ranging from 0° C. to 200° C. in
- the —NH-protecting group at the 3-position of compound (8a) is removed to give compound (9a).
- the reaction conditions are selected depending on the type of —NH-protecting group to be removed.
- the deprotection reaction may be preformed under conditions that are generally used for the protecting group.
- R p2 is a pivalyloxymethyl group
- the reaction can be carried out in methanol, or a mixed solution of methanol and tetrahydrofuran, using a base such as sodium methoxide, sodium hydride, or 1,8-diazabicyclo[5,4,0]-7-undecene at a temperature of 0° C. to 150° C.
- a base such as sodium methoxide, sodium hydride, or 1,8-diazabicyclo[5,4,0]-7-undecene at a temperature of 0° C. to 150° C.
- 0.1 to 2 equivalents of a base are preferably used.
- R p2 is a trimethylsilylethoxymethyl group
- the reaction can be carried out in a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane, using a fluoride reagent such as tetrabutyl ammonium fluoride or cesium fluoride at a temperature of 0° C. to 150° C.
- a fluoride reagent such as tetrabutyl ammonium fluoride or cesium fluoride at a temperature of 0° C. to 150° C.
- 1 to 5 equivalents of a fluoride reagent are preferably used.
- reaction conditions there are no particular limitations on the reaction conditions, and the reaction can be conducted under standard conditions for chlorination.
- the reaction can be carried out at a temperature ranging from 0° C. to 150° C. in a solvent such as phosphorus oxychloride. In this case, it is preferable to use a 10 to 200 times amount of halogenating agent by weight.
- R p3 is a t-butoxycarbonyl group or such, which is removed under the above-described conditions using phosphorus oxychloride or such, the protecting group should be reintroduced.
- reaction conditions for the protection there are no particular limitations on the reaction conditions for the protection.
- the reaction can be carried out using an —NH— protection reagent such as di-t-butyl dicarbonate, in a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane in the presence of a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, or triethylamine at 0 to 150° C.
- a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, or triethylamine at 0 to 150° C.
- compound (10a) is reacted with compound (11a-2) to give compound (11a).
- Compound (11a-2) includes alcohol compounds or phenol compounds represented by A 2 -OH, amine compounds represented by A 2 (R A )NH or such, and thiol compounds represented by A 2 -SH.
- compound (11a-2) is preferably used in an amount of 1 to 10 equivalents or 5 to 100 times by weight.
- Solvents for the reaction include acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, dimethoxyethane, methanol, and ethanol.
- the reaction can be carried out in the presence or absence of a base.
- Bases to be used in the reaction include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium hydride, sodium hydride, potassium hydride, butyllithium, methyllithium, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, and triethylamine.
- 1 to 10 equivalents of a base is preferably used.
- the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
- compound (10a) is reacted with compound (13a) in the presence of a metal catalyst to give compound (12a).
- a metal catalyst In this case, 1 to 50 equivalents of compound (13a) are preferably used.
- Solvents for the reaction include acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, dimethoxyethane, methanol, and ethanol.
- Metal catalysts include palladium catalyst and copper catalyst.
- Palladium catalysts include tetrakis triphenylphosphine palladium, palladium acetate, and dibenzylideneacetone palladium.
- Copper catalyst include copper iodide. It is preferable to use 0.01 to 2 equivalents of a metal catalyst.
- the reaction can be conducted in the presence of an organophosphorous ligand.
- organophosphorous ligand examples include o-tolyl phosphine and diphenylphosphinoferrocene. In this case, it is preferable to use 1 to 5 equivalents of an organophosphorous ligand to the metal catalyst.
- the reaction can be carried out in the presence or absence of a base.
- Bases to be used in the reaction include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium hydride, sodium hydride, potassium hydride, potassium phosphate, lithium bis trimethylsilyl amide, sodium bis trimethylsilyl amide, potassium bis trimethylsilyl amide, and triethylamine.
- the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
- compound (10a) is reacted with a cyanidation reagent to give compound (14a).
- cyanidation reagents include, for example, sodium cyanide and potassium cyanide. It is preferably used in an amount of 1 to 20 equivalents.
- Solvents for the reaction include, for example, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, dimethoxyethane, methanol, and ethanol.
- the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
- the cyano group of compound (14a) is hydrolyzed to give compound (15a).
- reaction conditions There are no particular limitations on the reaction conditions, and the reaction can be carried out under conditions generally used for the conversion of a cyano group to a carbamoyl group by hydrolysis.
- Solvents for the reaction include N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, dimethoxyethane, methanol, ethanol, and a mixed solvent of tetrahydrofuran and methanol.
- the reaction can be carried out in the presence or absence of a base.
- a base such as potassium hydroxide, sodium hydroxide, lithium hydroxide, or ammonia.
- the reaction can be achieved after adding an aqueous solution of hydrogen peroxide (preferably an aqueous solution of 30% hydrogen peroxide).
- the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
- R p3 of compound (16a) is removed to give compound (17a).
- Compounds (11a), (12a), (14a), (15a), and others can be used as compound (16a).
- the deprotection reaction for R p3 can be carried out under standard reaction conditions for removing an —NH-protecting group.
- R p3 is a t-butoxycarbonyl group
- the reaction can be carried out in the presence of an acid such as an anhydrous methanol solution of hydrogen chloride, an anhydrous ethanol solution of hydrogen chloride, an anhydrous dioxane solution of hydrogen chloride, trifluoroacetic acid, or formic acid.
- an acid such as an anhydrous methanol solution of hydrogen chloride, an anhydrous ethanol solution of hydrogen chloride, an anhydrous dioxane solution of hydrogen chloride, trifluoroacetic acid, or formic acid.
- compound (18a) is chlorinated to give compound (19a).
- the reaction conditions can be conducted under standard conditions for chlorination.
- the reaction can be carried out in a solvent such as phosphorus oxychloride at a temperature ranging from 0° C. to 150° C. Preferably 10 to 200 times by weight of chlorination reagent is used.
- R p3 is a t-butoxycarbonyl group or such, which is removed under the above-described condition using phosphorus oxychloride or such, the protecting group should be reintroduced.
- reaction conditions for the protection there are no particular limitations on the reaction conditions for the protection, and when R p3 is a t-butoxycarbonyl group, the reaction can be carried out using an —NH— protection reagent such as di-t-butyl dicarbonate, in a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, and dimethoxyethane, in the presence of a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, or triethylamine at a temperature ranging from 0° C. to 150° C.
- a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, potassium bicarbonate, sodium bicarbonate, or trieth
- compound (19a) is partially hydrolyzed to give compound (20a).
- the reaction is carried out in the presence of a base such as sodium acetate, potassium carbonate, or sodium hydroxide.
- a base such as sodium acetate, potassium carbonate, or sodium hydroxide.
- Solvents for the reaction include dimethyl sulfoxide, N-methylpyrrolidone, tetrahydrofuran, water, and mixtures thereof.
- the reaction can be conducted at a temperature ranging from 0° C. to 100° C.
- compound (20a) is reacted with compound (21a) to give compound (22a).
- the reaction can be conducted under the same conditions as used in [Step A2] of production method A.
- the reaction can be conducted under the same conditions as used in [Step A4] of production method A.
- compound (24a) is reacted with a halogenating agent to give compound (25a).
- the reaction can be conducted under the same conditions as used in [Step A5] of production method A.
- compound (25a) is chlorinated to give compound (26a).
- compound (25a) can be reacted with phosphorus oxychloride, phosphorus pentachloride, or a mixture thereof in a solvent or in the absence of a solvent at a temperature of 0° C. to 150° C.
- Solvents include, for example, toluene, acetonitrile, and dichloroethane.
- the reaction can be conducted under the same conditions as used in [Step A6] of production method A.
- Production Method B [Step B1]
- compound (1b) is benzylated and the sugar chain is cleaved to give compound (2b).
- Compound (2b) can be obtained by reacting compound (1b) with benzyl bromide in a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, 1,4-dioxane, tetrahydrofuran, dimethoxyethane, methanol, or ethanol, at a temperature of 0° C. to 150° C., adding 3 to 10 equivalents of hydrochloric acid, and incubating the mixture at a temperature of 0° C. to 150° C. to cleave the sugar moiety. It is preferable to use 1 to 3 equivalents of benzyl bromide.
- a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, 1,4-dioxane, tetrahydrofuran, dimethoxyethane, methanol, or ethanol,
- compound (2b) is reacted with a halogenating agent to give compound (3b).
- the halogenation reaction can be conducted under the same conditions as used in [Step A5] of production method A.
- compound (3b) is reacted with compound (4b) to give compound (5b).
- the reaction can be conducted under the same conditions as used in [Step A6] of production method A.
- compound (5b) is reacted with compound (5b-2) to give compound (6b).
- the reaction can be conducted under the same condition as used in [Step A2] of production method A.
- Compound (9b) represented by the formula: can be obtained by using compound (8b) represented by H-T 1a , instead of compound (7a) in [Step A6] of production method A described above under the same reaction conditions as used in [Step A6], and then appropriately applying [Step A7] to [Step A13] described above.
- Compound (10b) represented by the formula: can be obtained by using compound (8b) represented by H-T 1a , instead of compound (3b) in [Step B3] of production method B described above under the same reaction conditions as used in [Step B3] and then appropriately applying [Step B4] to [Step B6] described above.
- Preferable examples of compound (8b) include piperidin-3-yl carbamic acid t-butyl ester.
- compound (1c) is reacted with compound (1c-2) to give compound (2c).
- the reaction can be conducted under the same conditions as used in [Step A4] of production method A.
- Compound (3c) can be obtained, for example, by heating an ethanol solution of compound (2c) under reflux in the presence of an acid such as sulfuric acid or hydrochloric acid.
- an acid such as sulfuric acid or hydrochloric acid.
- the reaction conditions are not limited thereto. In this reaction, it is preferable to use one to two equivalents of an acid.
- compound (7c) is thioamidated to give compound (8c).
- Solvents for the reaction include methanol, ethanol, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, and dimethoxyethane.
- Thioamidation reagents include ammonium sulfide, sodium sulfide, and hydrogen sulfide. It is preferable to use 2 to 10 equivalents of a thioamidation reagent.
- the reaction is carried out in the presence of a base such as triethylamine or N,N-diisopropylethylamine.
- a base such as triethylamine or N,N-diisopropylethylamine.
- the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
- compound (8c) is reacted with a methylating reagent to give compound (9c).
- Methylating reagents include trimethyl oxonium tetrafluoroborate, methyl sulfate, methyl iodide, and trimethyl phosphite. It is preferable to use 1.0 to 1.5 equivalent of the methylating reagent.
- compound (9c) can be obtained by carrying out the reaction in a halogenated solvent such as dichloromethane at a temperature ranging from 0° C. to 50° C.
- a halogenated solvent such as dichloromethane
- compound (9c) can be obtained by carrying out the reaction in the presence of a base such as potassium carbonate, triethylamine, or N,N-diisopropylethylamine. In this case, it is preferable to use 1.0 to 1.5 equivalent of a base.
- Solvents for the reaction include acetone, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, and dimethoxyethane. The reaction can be performed at a temperature ranging from 0° C. to 100° C.
- reaction conditions for the hydrolysis There are no particular limitations on the reaction conditions for the hydrolysis.
- the reaction can be carried out in a mixed solvent of ethanol and water in the presence of an acid such as sulfuric acid, hydrochloric acid, or p-toluenesulfonic acid, at a temperature ranging from 0° C. to 80° C. In this case, it is preferable to use 5 to 50 equivalents of the acid.
- R p3 is a group, such as a t-butoxycarbonyl group, which is removed under the above-described condition, the protecting group should be reintroduced. There are no particular limitations on the reaction conditions for the introduction of this protecting group.
- R p3 is a t-butoxycarbonyl group
- the reaction can be carried out using a reagent such as t-butyl dicarbonate in a solvent such as dichloromethane, chloroform, N,N-dimethylformamide, or tetrahydrofuran, in the presence of a base such as pyridine, 4-aminopyridine, triethylamine, and N,N-diisopropylethylamine, at a temperature ranging from 0° C. to 80° C. In this case, it is preferable to use 2 to 3 equivalents of a base.
- reaction conditions for the reduction can be achieved by reacting compound (10c) with hydrogen in the presence of Raney nickel in a solvent such as benzene, ethanol, 2-propanol, or acetone, at a temperature ranging from 0° C. to 50° C., or alternatively reacting compound (10c) with a reducing agent such as sodium borohydride, in a solvent such as methanol, ethanol, or 2-methyl-2-propanol, or in a mixed solvent of water and tetrahydrofuran at a temperature ranging from 0° C.
- a solvent such as benzene, ethanol, 2-propanol, or acetone
- compound (10c) with a reducing agent such as sodium borohydride, in the presence of 1 to 5 equivalents of a mercury salt such as mercuric acetate in a solvent such as methanol, ethanol, or 2-methyl-2-propanol at a temperature ranging from 0° C. to 50° C. It is preferable to use two to three equivalents of a reducing agent.
- a reducing agent such as sodium borohydride
- compound (11c) is subjected to an oxidation reaction to give compound (12c).
- compound (12c) can be obtained by carrying out the reaction in a solvent such as dichloromethane or chloroform, at a temperature ranging from 20° C. to 80° C.
- compound (12c) can also be obtained by carrying out the reaction under standard conditions for the oxidation of a primary alcohol to aldehyde, such as Swern oxidation. It is preferable to use 5 to 20 equivalents of an oxidant.
- compound (12c) is reacted with compound (13c) to give compound (17c).
- compound (12c) is reacted with compound (13c) to give compound (17c).
- Compound (17c) can be obtained, for example, by combining compounds (12c) and (13c) in a solvent such as methanol, ethanol, 1-methyl-2-pyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane, or in the absence of solvent, and reacting the mixture at a temperature of 20° C. to 150° C.
- a solvent such as methanol, ethanol, 1-methyl-2-pyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane
- the reaction conditions are not limited thereto.
- compound (12c) is reacted with hydrazine to give compound (15c).
- the reaction can be conducted under the same conditions as used in [Step C11] of production method C. It is preferable to use 2 to 10 equivalents of hydrazine.
- a substitution reaction is carried out using compound (15c) and compound (16c) to give compound (17c).
- the reaction can be conducted under the same conditions as used in [Step A2] of production method A. It is preferable to use 1 to 3 equivalents of compound (16c).
- reaction conditions for the hydrolysis there are no particular limitations on the reaction conditions for the hydrolysis.
- compound (19c) can be obtained by incubating compound (18c) in the presence of a base at a temperature ranging from 0° C. to 100° C.
- Solvents for the reaction include methanol, ethanol, tetrahydrofuran, water, or mixtures thereof.
- Bases include lithium hydroxide, sodium hydroxide, and potassium hydroxide. It is preferable to use 1 to 2 equivalents of a base.
- compound (19c) is reacted with a reducing agent to give compound (20c).
- the reduction can be achieved under a standard condition for the reduction of carboxylic acid to methyl alcohol.
- Reducing agents include borane derivatives such as borane-tetrahydrofuran complex and borane-methyl sulfide complex, and sodium borohydride. It is preferable to use 5 to 30 equivalents of a reducing agent.
- compound (20c) can be obtained by carrying out the reaction using a solvent such as 1,4-dioxane, tetrahydrofuran, or dimethoxyethane at a temperature ranging from ⁇ 78° C. to 35° C.
- a solvent such as 1,4-dioxane, tetrahydrofuran, or dimethoxyethane at a temperature ranging from ⁇ 78° C. to 35° C.
- compound (19c) when sodium borohydride is used as a reducing agent, first, compound (19c) is reacted with an activator such as isobutyl chloroformate, at a temperature ranging from —78° C. to 20° C., then reacted with a reducing agent such as sodium borohydride at a temperature ranging from ⁇ 78° C. to 35° C., to obtain compound (20c).
- Solvents for the reaction include 1,4-dioxane, tetrahydrofuran, and dimethoxyethane.
- compound (21c) is reacted with a silylating agent in the presence of a base to give compound (22c).
- Solvents for the reaction include dichloromethane, N,N-dimethylformamide, 1,4-dioxane, tetrahydrofuran, and dimethoxyethane.
- Bases include imidazole, pyridine, 4-dimethylaminopyridine, triethylamine, and N,N-diisopropylethylamine.
- Silylating agents include t-butyldimethylchlorosilane, and t-butylchlorodiphenylsilane. It is preferable to use 1.0 to 1.5 equivalent of a base and 1.0 to 1.5 equivalent of a silylating agent.
- the reaction can be conducted at a temperature ranging from 0° C. to 80° C.
- the reaction can be conducted under the same condition as used in [Step C7] of production method C.
- compound (23c) is hydrolyzed to give compound (24c).
- Compound (24c) can be obtained by carrying out the reaction in a mixed solvent of ethanol and water in the presence of an acid such as sulfuric acid, hydrochloric acid, or p-toluenesulfonic acid, at a temperature ranging from 50° C. to 100° C.
- an acid such as sulfuric acid, hydrochloric acid, or p-toluenesulfonic acid
- —NH— is re-protected through a protection reaction.
- the reaction can be carried out using a reagent such as t-butyl dicarbonate, in a solvent such as dichloromethane, chloroform, N,N-dimethylformamide, or tetrahydrofuran, in the presence of a base such as pyridine, 4-aminopyridine, triethylamine, or N,N-diisopropyl ethylamine, at a temperature ranging from 0° C. to 80° C.
- a base such as pyridine, 4-aminopyridine, triethylamine, or N,N-diisopropyl ethylamine
- compound (1d-2) includes, for example, alkyl1 halides such as iodomethane, iodoethane, iodopropane, benzyl bromide, 2-bromoacetophenone, chloromethyl benzyl ether, and bromoacetonitrile, alkenyl halides such as allyl bromide and 1-bromo-3-methyl-2-butene; and alkynyl halides such as propargyl bromide and 1-bromo-2-butyne. It is preferable to use 1 to 1.5 equivalent of compound (1d-2).
- alkyl1 halides such as iodomethane, iodoethane, iodopropane, benzyl bromide, 2-bromoacetophenone, chloromethyl benzyl ether, and bromoacetonitrile
- alkenyl halides such as allyl bromide and 1-bromo-3-
- Solvents for the reaction include N,N-dimethylformamide, N-methylpyrrolidone, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, and dichloromethane.
- the reaction can be carried out in the presence or absence of a base.
- Bases to be used in the reaction include 1,8-diazabicyclo[5,4,0]undecene, triethylamine, N,N-diisopropylethylamine, and sodium hydride. In this case, it is preferable to use 1 to 1.5 equivalent of the base.
- the reaction can be conducted at a temperature ranging from 0° C. to 150° C.
- Solvents for the reaction include a mixed solvent of water and a solvent from N,N-dimethylformamide, N-methylpyrrolidone, tetrahydrofuran, 1,2-dimethoxyethane, and 1,4-dioxane.
- Nitrite salts include sodium nitrite and potassium nitrite. It is preferable to use 3 to 5 equivalents of a nitrite.
- the reaction can be conducted at a temperature ranging from 20° C. to 120° C.
- compound (3d) is reacted with ammonia to give compound (4d). It is preferable to use 10 to 20 equivalents of ammonia.
- the reaction can be carried out in a solvent such as methanol, ethanol, or 1,4-dioxane at a temperature ranging from 20° C. to 200° C.
- a solvent such as methanol, ethanol, or 1,4-dioxane
- compound (4d) is subjected to catalytic reduction under hydrogen atmosphere or in the presence of 2 to 3 equivalents of hydrazine using a metal catalyst to give compound (5d).
- Solvents for the reaction include methanol, ethanol, N,N-dimethylformamide, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, water, or a mixed solvent thereof.
- Metal catalysts include palladium carbon, platinum oxide, and Raney nickel. It is preferable to use a metal catalyst in the amount of 0.5 to 10% by weight. The reaction can be conducted at a temperature ranging from 0° C. to 150° C.
- the reaction is carried out in the presence of a carboxylic anhydride such as acetic anhydride.
- a carboxylic anhydride such as acetic anhydride.
- Orthoformate esters include methyl orthoformate, and ethyl orthoformate. It is preferable to use 1 to 20 times as much orthoformate ester by weight and 3 to 10 equivalents of carboxylic anhydride.
- the reaction can be conducted at a temperature ranging from 20° C. to 200° C.
- Protecting reagents include N,N-dimethylsulfamoyl chloride, trityl chloride, di-t-butyl dicarbonate, and benzyl bromide. It is preferable to use 1 to 1.5 equivalent of a protecting reagent.
- Solvents for the reaction include dichloromethane, chloroform, carbon tetrachloride, toluene, N,N-dimethylformamide, and tetrahydrofuran.
- Bases include pyridine, 4-dimethylaminopyridine, 1,8-diazabicyclo[5,4,0]undecene, triethylamine, and N,N-diisopropylethylamine.
- the protecting reagent is di-t-butyl dicarbonate
- 0.005 to 0.1 equivalent of 4-dimethylaminopyridine is used preferably.
- the reaction can be conducted at a temperature ranging from 20° C. to 200° C.
- reaction conditions there are no particular limitations on -the reaction conditions.
- the reaction is carried out as follows.
- Compound (7d) is reacted with a base at a temperature ranging from ⁇ 100° C. to 20° C., and then a chlorinating reagent is reacted thereto.
- This reaction produces compound (8d).
- Compound (8d) can also be obtained by reacting compound (7d) with a base in the presence of a chlorination reagent.
- Solvents for the reaction include, for example, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, and 1,4-dioxane.
- Bases include n-butyllithium, t-butyllithium, lithium diisopropylamide, lithium bis(trimethylsilyl)amide, and magnesium diisopropylamide. It is preferable to use 1 to 1.5 equivalent of a base.
- Chlorinating reagents include hexachloroethane, and N-chloro succinimide. It is preferable to use 1 to 3 equivalents of a chlorination reagent.
- compound (8d) is reacted with compound (9d) to give compound (10d).
- the reaction can be conducted under the same conditions as used in [Step A6] of production method A.
- R p3 of compound (11d) is removed to give compound (12d).
- the reaction can be conducted under the same condition as used in [Step A13] of production method A.
- R 1 is a benzyloxymethyl group
- compound (11d) is reacted with 3 to 10 equivalents of boron tribromide, boron trichloride, or such in a solution such as dichloromethane at a temperature ranging from ⁇ 100° C. to 20° C. This reaction produces compound (13d).
- —NH— is re-protected through a protection reaction.
- the reaction can be carried out using a reagent such as di-t-butyl dicarbonate, in a solvent such as dichloromethane, chloroform, N,N-dimethylformamide, or tetrahydrofuran, in the presence of a base such as pyridine, 4-aminopyridine, triethylamine, or N,N-diisopropylethylamine, at a temperature ranging from 0° C. to 80° C.
- a base such as pyridine, 4-aminopyridine, triethylamine, or N,N-diisopropylethylamine, at a temperature ranging from 0° C. to 80° C.
- the reaction is not limited thereto.
- compound (13d) is reacted with compound (13d-2) to give compound (14d).
- the reaction can be conducted under the same conditions as used in [Step D1] of production method D.
- R p3 of compound (14d) is removed to give compound (12d).
- the reaction can be conducted under the same conditions as used in [Step A13] of production method A.
- the deprotection can be achieved under standard reaction conditions depending on the type of protecting group.
- the deprotection can be achieved by carrying out the reaction using a base such as sodium hydroxide, potassium carbonate, and ammonia, in tetrahydrofuran, N,N-dimethylformamide, methanol, ethanol, water, or a mixed solvent thereof at a temperature ranging from 0° C. to 100° C.
- a base such as sodium hydroxide, potassium carbonate, and ammonia
- X is introduced into compound (15d) to give compound (16d).
- the reaction can be conducted using X—U 2 under the same conditions as used in [Step A4] of production method A.
- An alcohol (X—OH) can be introduced using Mitsunobu's reaction.
- compound (16d) can be obtained by reacting an alcohol (X—OH) with an azodicarboxylic acid dialkyl ester and triphenylphosphine in a solvent such as tetrahydrofuran, at a temperature ranging from ⁇ 70° C. to 50° C.
- the reaction can be conducted under the same conditions as used in [Step A6] of production method A.
- Compound (1e) represented by the formula: can be obtained by using compound (8b) represented by H-T 1a , instead of compound (6c), in [Step C5] or [Step C15] of production method C described above under the same reaction conditions as used in [Step C5], and then appropriately applying [Step C6] to [Step C21] described above.
- ester group of compound (1f) is hydrolyzed to give compound (2f).
- the reaction can be conducted under the same conditions as used in [Step C16] of production method C.
- Solvents for the reaction include methanol, ethanol, tetrahydrofuran, water, or mixtures thereof.
- Reducing agents includes, iron, tin, and zinc.
- Catalysts include hydrochloric acid and ammonium salts such as ammonium chloride. The reaction can be conducted at a temperature ranging from 20° C. to 120° C.
- reaction conditions there are no particular limitations on the reaction conditions.
- Compound (2h) can be obtained by reacting compound (1h) with hydrogen peroxide in the presence of a base at a temperature ranging from ⁇ 20° C. to 50° C.
- Solvents include methanol, ethanol, tetrahydrofuran, water, or a solvent mixture thereof.
- Bases include ammonia and alkyl amines such as triethylamine.
- compound (1i) is reacted with an alkyl metal agent or an aryl metal agent to give compound (2i).
- reaction conditions there are no particular limitations on the reaction conditions.
- the reaction is carried out as follows.
- Compound (1i) may be reacted with an agent such as alkyllithium, aryllithium, alkyl Grignard reagent, or aryl Grignard reagent, in a solvent such as diethyl ether or tetrahydrofuran, at a temperature ranging from ⁇ 100° C. to 100° C.
- the compound may be reacted with alkylzinc or arylzinc in a solvent such as N,N-dimethylformamide or 1-methyl-2-pyrrolidone, at a temperature ranging from 0° C. to 50° C.
- compound (2i) is oxidized to give compound (3i).
- a typical reagent that is generally used in the oxidation of an alcohol can be used as the oxidant.
- manganese dioxide can be used as the oxidant in a solvent such as dichloromethane or chloroform, at a temperature within the range of 20° C. to 100° C.
- sulfur trioxide pyridine can be used as the oxidant in a solvent such as dimethyl sulfoxide, at a temperature within the range of 20° C. to 100° C.
- Dess-Martin periodinane may be used in a solvent such as dichloromethane or chloroform, at a temperature within the range of ⁇ 50 to 50° C.
- compound (1j) is reacted with a cyanidation agent in the presence of a catalyst to give compound (2j).
- Cyanidation agents include sodium cyanide, and potassium cyanide.
- Catalysts include acetic acid.
- Solvents include, for example, acetonitrile. The reaction can be conducted at a temperature ranging from 0° C. to 100° C.
- the nitrile group of compound (2j) is hydrolyzed to give compound (3j).
- the reaction can be conducted under the same conditions as used in [Step H1] of production method H.
- compound (4j) is reacted with compound (5j) to give compound (6j).
- the reaction can be conducted under the same conditions as used in [Step C11] of production method C.
- Dehydrating agents include, for example, phosphorus oxychloride.
- Bases include alkyl amines such as triethylamine.
- Solvents include dichloromethane, and chloroform.
- the reaction can be carried out in the absence of solvent. The reaction can be conducted at a temperature ranging from 0° C. to 100° C.
- Compound (5k) can be obtained, for example, by reacting a mixture of compounds (3k) and (4k) in a solvent such as methanol, ethanol, 1-methyl-2-pyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane, or in the absence of solvent at a temperature ranging from 20° C. to 200° C.
- a solvent such as methanol, ethanol, 1-methyl-2-pyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane
- the reaction conditions are not limited thereto.
- compound (5k) is chlorinated to give compound (6k).
- the reaction can be conducted under the same conditions as used in [Step D7] of production method D.
- the deprotection reaction for R p5 can be carried out under standard reaction conditions for removing an —NH-protecting group.
- R p5 is a benzyl group
- the reaction can be achieved using a metal such as lithium or sodium in liquid ammonia at a temperature within the range of ⁇ 78° C. to ⁇ 30° C.
- Oxidants include salts such as iron (III) chloride.
- Solvents include methanol, ethanol, and water. The reaction can be conducted at a temperature ranging from 20° C. to 100° C.
- —NH— is re-protected through a protection reaction.
- the reaction can be carried out using a reagent such as di-t-butyl dicarbonate, in a solvent such as dichloromethane, chloroform, N,N-dimethylformamide, or tetrahydrofuran, in the presence of a base such as pyridine, 4-aminopyridine, triethylamine, or N,N-diisopropylethylamine, at a temperature ranging from 0° C. to 80° C.
- a base such as pyridine, 4-aminopyridine, triethylamine, or N,N-diisopropylethylamine, at a temperature ranging from 0° C. to 80° C.
- the reaction is not limited thereto.
- the reaction can be conducted at a temperature ranging from 20° C. to 150° C.
- Solvents for the reaction include methanol, ethanol, water, and a mixed solvent thereof.
- Reducing agents include tin salts such as tin chloride.
- Solvents include concentrated hydrochloric acid. The reaction can be conducted at a temperature ranging from 20° C. to 150° C.
- the reaction can be achieved using a solvent such as acetonitrile or tetrahydrofuran.
- the reaction can be conducted at a temperature ranging from 20° C. to 100° C.
- Compound (7n) can be obtained, for example, by reacting compound (6n) with osmic acid and sodium periodate in a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, or water at a temperature ranging from 20° C. to 100° C.
- a solvent such as tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, or water at a temperature ranging from 20° C. to 100° C.
- the reaction conditions are not limited to this example.
- reaction conditions There are no particular limitations on the reaction conditions.
- the reaction can be conducted under standard reaction conditions to be used for chlorination.
- Compound (8n) can be obtained, for example, by using a reagent such as phosphorus pentachloride in a solvent such as phosphorus oxychloride, at a temperature of 0° C. to 150° C.
- Bases include sodium hydride and lithium diisopropylamide.
- Solvents include, for example, tetrahydrofuran and N,N-diformamide. The reaction can be conducted at a temperature ranging from 0° C. to 1 00° C.
- the ester of compound (3o) is hydrolyzed to give compound (4o).
- the reaction can be conducted under the same condition as used in [Step C16] of production method C.
- compound (4o) is reacted with diphenylphosphoryl azide in the presence of a base to give compound (5o).
- Solvents for the reaction include toluene, t-butanol, tetrahydrofuran, and dichloromethane.
- Bases include tertiary amines such as triethylamine and diisopropylethylamine. The reaction can be conducted at a temperature ranging from ⁇ 50° C. to ⁇ 50° C.
- the reaction can be achieved in t-butanol at a temperature ranging from 50° C. to 100° C.
- the nitrite group of compound (6o) is hydrolyzed to give compound (7o).
- the reaction can be conducted under the same conditions as used in [Step H1] of production method H.
- Acids include hydrochloric acid, sulfuric acid, and trifluoroacetic acid.
- Solvents include methanol, ethanol, 1,4-dioxane, water, and mixtures thereof. The reaction can be conducted at a temperature ranging from 0° C. to 50° C. Production Method P [Step P1]
- a typical NH group-protecting reagent that is generally used in protecting NH groups can be used as an NH group-protecting reagent.
- R p3 is a t-butoxycarbonyl group
- the reaction can be achieved at a temperature ranging from 0° C. to 80° C. using a reagent such as di-t-butyl dicarbonate, in a solvent such as dichloromethane, chloroform, N,N-dimethylformamide, and tetrahydrofuran, in the presence of a base such as pyridine, 4-aminopyridine, triethylamine, and N,N-diisopropylethylamine.
- a base such as pyridine, 4-aminopyridine, triethylamine, and N,N-diisopropylethylamine.
- Reaction solvents include tetrahydrofuran, methanol, and ethanol.
- Acids include inorganic acids such as hydrochloric acid and sulfuric acid. The reaction can be conducted at a temperature ranging from 0° C. to 100° C.
- Bases include sodium hydride, potassium t-butoxide, and 8-diazabicyclo[5.4.0]-7-undecene.
- Solvents include dichloromethane, tetrahydrofuran, and N,N-dimethylformamide. The reaction can be conducted at a temperature ranging from 0° C. to 100° C.
- Methanol can be used as solvent.
- the reaction can be conducted at a temperature ranging from 0° C. to 80° C.
- Reaction solvents include methanol, ethanol, and water.
- the reaction can be conducted at a temperature ranging from 20° C. to 150° C.
- substitution reaction is conducted under the same conditions as used in [Step A4] of production method A.
- substitution reaction is conducted under the same conditions as used in [step A4] of production method A.
- compound (2s) is reacted with a halogenating agent, to give compound (3s).
- the halogenation reaction is conducted under the same conditions as used in [Step A5] of production method A.
- the coupling reaction is conducted under the same conditions as used in [Step A6] of production method A.
- substitution reaction is conducted under the same conditions as used in [step A4] of production method A.
- the reaction is conducted under the same conditions as used in [Step A6] of production method A.
- compound (4t) is alkylated at the 1-position, and then R p3 is removed to give compound (5t).
- the alkylation reaction is conducted under the same conditions as used in [Step A2] of production method A.
- substitution reaction is conducted under the same conditions as used in [Step A4] of production method A.
- the halogenation reaction is conducted under the same conditions as used in [Step A5] of production method A.
- the reaction is conducted under the same conditions as used in [Step A6] of production method A.
- compound (5u) is alkylated at the 1-position, and then R p3 is removed to give compound (6u).
- the alkylation reaction is conducted under the same conditions as used in [Step A2] of production method A.
- compound (1v) is alkylated at the 1-position, and is then hydrolyzed to give compound (2v).
- the alkylated compound can be obtained by incubating a compound represented by formula (1v-2), such as methyl bromoacetate or ethyl bromoacetate; in the presence of a base, such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium hydride, sodium hydride, potassium hydride, butyl lithium, methyl lithium, lithium bis-trimethylsilylamide, sodium bis-trimethylsilylamide, or potassium bis-trimethylsilylamide; in a solvent, such as dimethylsulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, or toluene; at a temperature ranging from 0° C. to 150° C.
- a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium
- reaction conditions for the hydrolysis there are no particular limitations on the reaction conditions for the hydrolysis.
- the reaction can be carried out using an aqueous solution lithium hydroxide, sodium hydroxide, or potassium hydroxide; in a solvent, such as methanol, ethanol, propanol, dimethylsulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, or tetrahydrofuran; at a temperature ranging from 0° C. to 150° C.
- reaction conditions for the amidation there are no particular limitations on the reaction conditions for the amidation.
- the reaction can be carried out using an acylating agent such as ethyl chloroformate or isobutylchloroformate; in the presence of an organic base such as triethylamine or N,N-diisopropylethylamine; in a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane; with a corresponding amine at a temperature ranging from 0° C. to 150° C.
- an acylating agent such as ethyl chloroformate or isobutylchloroformate
- organic base such as triethylamine or N,N-diisopropylethylamine
- solvent such as acetonitrile, N,N-dimethylformamide,
- the alkylation reaction is conducted under the same conditions as used in [Step A2] of production method A.
- the amidation can be conducted using a condensation agent such as 1,1′-carbonyldiimidazole or diethyl cyanophosphonate; in a solvent such as dimethylsulfoxide, N,N-dimethylformamide, or tetrahydrofuran. If required, it is possible to add an organic base, such as triethylamine, to the reaction.
- a condensation agent such as 1,1′-carbonyldiimidazole or diethyl cyanophosphonate
- a solvent such as dimethylsulfoxide, N,N-dimethylformamide, or tetrahydrofuran.
- an organic base such as triethylamine
- compound (1w) is hydroxy-iminated and the generated hydroxyl group is treated by sulfonylation, followed by removal of R p3 , to give compound (2w).
- the hydroxy imination reaction can be carried out using a reagent such as hydroxylamine hydrochloride; in the presence of a base such as potassium acetate or sodium acetate; in a solvent such as water, methanol, ethanol, propanol, dimethylsulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, or toluene.
- a reagent such as hydroxylamine hydrochloride
- a base such as potassium acetate or sodium acetate
- a solvent such as water, methanol, ethanol, propanol, dimethylsulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, or toluene.
- the sulfonylation can be conducted using methane sulfonyl chloride, tosyl chloride, 4-nitrobenzensulfonyl chloride, or similar; in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, or N,N-dimethylaminopyridine; in a solvent such as dichloromethane, chloroform, dioxane, tetrahydrofuran, toluene, or pyridine; at a temperature ranging from 0° C. to 150° C.
- a base such as triethylamine, diisopropylethylamine, pyridine, or N,N-dimethylaminopyridine
- a solvent such as dichloromethane, chloroform, dioxane, tetrahydrofuran, toluene, or pyridine
- reaction conditions there are no particular limitations on the reaction conditions.
- the reaction can be conducted using a reducing agent such as lithium borohydride, sodium borohydride, or potassium borohydride; in a solvent such as methanol, ethanol, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, dimethoxyethane, or in a mixed solution of these solvents; at a temperature ranging from 0° C. to 150° C.
- the alkylation reaction can be carried out using a halogenated alkyl; in the presence of a base such as lithium hydride, sodium hydride, potassium hydride, lithium hydroxide, sodium hydroxide, or potassium hydroxide; in a solvent such as methanol, ethanol, acetonitrile, N,N-diethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane.
- a base such as lithium hydride, sodium hydride, potassium hydride, lithium hydroxide, sodium hydroxide, or potassium hydroxide
- a solvent such as methanol, ethanol, acetonitrile, N,N-diethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane.
- compound (2x) is fluorinated to give compound (6x).
- reaction conditions there are no particular limitations on the reaction conditions.
- the reaction can be carried out using a fluorinating agent such as Tris dimethylaminosulfate trifluoride; in a solvent such as dichloromethane, 1,2-dichloroethane, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane; at a temperature ranging from ⁇ 78° C. to 150° C.
- a fluorinating agent such as Tris dimethylaminosulfate trifluoride
- a solvent such as dichloromethane, 1,2-dichloroethane, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane
- compound (1x) is fluorinated to give compound (8x).
- reaction conditions there are no particular limitations on the reaction conditions.
- the reaction can be carried out using a fluorinating agent such as Tris dimethylaminosulfate trifluoride; in a solvent such as dichloromethane, 1,2-dichloroethane, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane; at a temperature ranging from ⁇ 78° C. to 150° C.
- a fluorinating agent such as Tris dimethylaminosulfate trifluoride
- a solvent such as dichloromethane, 1,2-dichloroethane, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane
- compound (2x) is subjected to the Wittig-Homer-Emmons reaction, to give compound (10x).
- reaction conditions there are no particular limitations on the reaction conditions.
- a reagent such as a phosphonium salt or phosphonate ester
- a base such as lithium hydride, sodium hydride, potassium hydride, potassium t-butoxide, or butyl lithium
- a solvent such as dichloromethane, 1,2-dichloroethane, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane; at a temperature ranging from ⁇ 78° C. to 150° C.
- the reduction can be conducted in the presence of a metal catalyst, such as palladium carbon, platinum oxide, or Raney nickel; in a solvent, such as methanol, ethanol, propanol, dimethylsulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, or toluene; in a hydrogen atmosphere at a temperature ranging from 0° C. to 150° C.
- a metal catalyst such as palladium carbon, platinum oxide, or Raney nickel
- a solvent such as methanol, ethanol, propanol, dimethylsulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, or toluene
- R p3 is removed from compounds (2x), (4x), (6x), (8x), (10x), and (12x) to give compounds (3x), (5x), (7x), (9x), (11x), and (13x), respectively.
- the hydrolysis can be conducted using an aqueous solution such as lithium hydroxide, sodium hydroxide, potassium hydroxide; in a solvent, such as methanol, ethanol, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane; at a temperature ranging from 0° C. to 150° C.
- aqueous solution such as lithium hydroxide, sodium hydroxide, potassium hydroxide
- a solvent such as methanol, ethanol, acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane
- the amidation reaction is conducted under the same conditions as used in [Step V6] of production method V.
- R p3 is removed from compounds (2y) and (4y), to give compounds (3y) and (5y), respectively.
- the reaction can be conducted using an alkylating agent such as benzyl bromide; in the presence of a base such as cesium carbonate, lithium carbonate, sodium carbonate, or potassium carbonate; in a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane; at a temperature ranging from 0° C. to 150° C.
- an alkylating agent such as benzyl bromide
- a base such as cesium carbonate, lithium carbonate, sodium carbonate, or potassium carbonate
- a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane
- the reaction can be conducted using an alkylating agent such as chloromethylpivalate; in the presence of a base such as cesium carbonate, lithium carbonate, sodium carbonate, or potassium carbonate; in a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane; at a temperature ranging from 0° C. to 150° C.
- an alkylating agent such as chloromethylpivalate
- a base such as cesium carbonate, lithium carbonate, sodium carbonate, or potassium carbonate
- a solvent such as acetonitrile, N,N-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, tetrahydrofuran, or dimethoxyethane
- the reaction conditions vary depending on the types of protecting groups to be used.
- the protecting group is a benzyl group
- the reaction can be conducted in the presence of a metal catalyst, such as palladium carbon, platinum oxide, or Raney nickel; in a solvent such as methanol, ethanol, propanol, dimethylsulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, or toluene; in a hydrogen atmosphere at a temperature ranging from 0° C. to 150° C.
- a metal catalyst such as palladium carbon, platinum oxide, or Raney nickel
- a solvent such as methanol, ethanol, propanol, dimethylsulfoxide, N,N-dimethylformamide, N-methylpyrrolidone, dioxane, tetrahydrofuran, or toluene
- solvent such as methanol, ethanol, propanol, dimethylsul
- substitution reaction is conducted under the same conditions as used in [Step A4] of production method A.
- the reaction conditions vary depending on the types of protecting groups to be used.
- the protecting group is a pivalyloxymethyl group
- the reaction can use a base such as sodium methoxide, sodium hydride, or diazabicyclo-undec-7-ene; a solvent such as methanol or a mixed solvent of methanol and tetrahydrofuran; at a temperature ranging from 0° C. to 150“C.
- a base such as sodium methoxide, sodium hydride, or diazabicyclo-undec-7-ene
- a solvent such as methanol or a mixed solvent of methanol and tetrahydrofuran
- compound (1aa) is reacted with a halogenating agent, to give compound (2aa).
- the halogenation reaction is conducted under the same conditions as used in [Step A5] of production method A.
- the reaction is conducted under the same conditions as used in [Step A6] of production method A.
- the deprotection reaction is conducted under the same conditions as used in [Step Z3] of production method Z.
- substitution reaction is conducted under the same conditions as used in [Step A4] of production method A.
- the deprotection reaction is conducted under the same conditions as used in [Step Z5] of production method Z.
- R p3 is removed from compound (7aa) to give compound (8aa).
- the reaction is conducted under the same conditions as used in [Step Z2] of production method Z.
- the deprotection reaction is conducted under the same conditions as used in [Step Z3] of production method Z.
- substitution reaction is conducted under the same conditions as used in [Step A4] of production method A.
- compound (4bb) is reacted with a halogenating agent, to give compound (5bb).
- the halogenation reaction is conducted under the same conditions as used in [Step A5] of production method N.
- the reaction is conducted under the same conditions as used in [Step A6] of production method A.
- the deprotection reaction is conducted under the same conditions as used in [Step Z5] of production method Z.
- substitution reaction is conducted under the same conditions as used in [Step A4] of production method A.
- the deprotection reaction is conducted under the same conditions as used in [Step Z5] of production method Z.
- R p3 is removed from compound (10bb), to give compound (11bb).
- substitution reaction is conducted under the same conditions as used in [Step A4] of production method A.
- substitution reaction is conducted under the same conditions as used in [Step A4] of production method A.
- R p3 is removed from compounds (1cc) and (2cc), to give compounds (3cc) and (4cc), respectively.
- the methods described above are representative methods for producing compounds (I) and (II) of the present invention.
- the starting compounds and various reagents to be used in the methods for producing the compounds of the present invention may be salts, hydrates, or solvates, depending on the type of starting materials and solvents to be used, and are not limited providing they do not inhibit the reactions.
- the types of solvents to be used depend on the types of starting compounds and reagents to be used, and are not limited providing they dissolve starting materials to some extent and do not inhibit the reactions.
- various isomers of compounds (I) and (II) of the present invention can be purified and isolated by typical isolation techniques including recrystallization, diastereomer salt method, enzyme-based resolution method, and various chromatographic methods (for example, thin layer chromatography, column chromatography, and gas chromatography).
- the pharmaceutical agents of the present invention can be obtained by combining active ingredients, i.e., a DPPIV inhibitor and a biguanide agent or a pharmaceutical agent that is able to enhance the effects of active circulating GLP-2.
- active ingredients i.e., a DPPIV inhibitor and a biguanide agent or a pharmaceutical agent that is able to enhance the effects of active circulating GLP-2.
- the active ingredients described above may be formulated separately or in combination, and they may be mixed with pharmaceutically acceptable carriers, excipients, binders, and similar.
- the dosage form of the pharmaceutical agents described above includes oral preparations, for example, granules, microgranules, powders, tablets, coated tablets, capsules, and syrups; and non-oral preparations, for example, injections (intravenous injections, subcutaneous injections, intramuscular injections, etc.), suppositories, and external preparations (transdermal therapeutics, ointments, etc.).
- oral preparations for example, granules, microgranules, powders, tablets, coated tablets, capsules, and syrups
- non-oral preparations for example, injections (intravenous injections, subcutaneous injections, intramuscular injections, etc.), suppositories, and external preparations (transdermal therapeutics, ointments, etc.).
- Such formulations can be achieved by using typical excipients, binders, disintegrating agents, lubricants, colorants, flavoring agents; and if required, stabilizers, emulsifiers, absorbefacients, detergents, pH adjustors, preservatives, antioxidants, etc., and materials commonly used as ingredients of pharmaceutical preparations according to conventional methods.
- These materials include, for example, (1) animal and vegetable oils, such as soya bean oil, beef tallow, and synthetic glyceride; (2) hydrocarbons, such as liquid paraffin, squalane, and solid paraffin; (3) ester oils, such as octyldodecyl myristate and isopropyl myristate; (4) higher alcohols, such as cetostearyl alcohol and behenyl alcohol; (5) silicon resins; (6) silicon oils; (7) detergents, such as polyoxyethylene fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene hydrogenated castor oil, and polyoxyethylene polyoxypropylene block co-polymer; (8) water-soluble polymers, such as hydroxyethyl cellulose, poly-acrylic acid, carboxyvinyl polymer, polyethylene glycol, polyvinylpyrrolidone, and methyl cellulose; (9) lower alcohol
- the excipients include, for example, lactose, corn starch, white sugar, glucose, mannitol, sorbitol, crystal cellulose, and silicon dioxide.
- the binders include, for example, polyvinyl, alcohol, polyvinyl ether, methyl cellulose, ethyl cellulose, arabic gum, tragacanth, gelatin, shellac, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinylpyrrolidone, polypropylene glycol-polyoxyethylene block co-polymer, meglumine, calcium citrate, dextrin, and pectin.
- the disintegrating agents include, for example, starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextrin, pectin, and calcium carboxymethyl cellulose.
- the lubricants include, for example, magnesium stearate, talc, polyethylene glycol, silica, and hydrogenated vegetable oil.
- the colorants include those that are pharmaceutically acceptable.
- the flavoring agents include cocoa powder, peppermint camphor, aromatic powder, peppermint oil, Borneo camphor, and cinnamon powder.
- the antioxidants include those that are pharmaceutically acceptable, such as ascorbic acid and ⁇ -tocopherol.
- the oral preparation can be produced by combining the active ingredients with an excipient; and if required, a binder, a disintegrating agent, a lubricant, a colorant, a flavoring agent, or such; and formulating the mixture into powders, microgranules, granules, tablets, coated tablets, capsules, or such; according to conventional methods. Tablets-and granules may be coated with sugar or gelatin, or if required, any other appropriate coatings.
- Solutions such as syrups or injectable preparations to be administered, can be formulated by combining a compound of the present invention with a pH adjustor, a solubilizing agent, an isotonizing agent, or such; and if required, with an auxiliary solubilizing agent, a stabilizer, a buffer, a suspending agent, an antioxidant, or the like; according to conventional methods.
- the solution may be freeze-dried.
- preferred suspending agents are: methylcellulose, Polysorbate 80, hydroxyethyl cellulose, arabic gum, powdered tragacanth, sodium carboxymethylcellulose, and polyoxyethylenesorbitan mono-laurate.
- auxiliary solubilizing agents are: polyoxyethylene hydrogenated castor oil, Polysorbate 80, nicotinamide, and polyoxyethylenesorbitan mono-laurate.
- preferred stabilizers are: sodium sulfite, sodium metasulfite, and ether.
- preferred preservatives are: methyl para-oxybenzoate, ethyl para-oxybenzoate, sorbic acid, phenol, cresol, and chlorocresol.
- external preparations of the present invention can contain pH adjustors, antioxidants, chelating agents, antibacterial/antifungal agents, colorants, and flavoring agents, as required. Additionally, external preparations of the present invention can also contain agents that induce differentiation, promote blood flow, activate cells, and antimicrobials, anti-inflammatories, vitamins, amino acids, humectants, keratolytics, and others, if required.
- a DPPIV inhibitor and either a biguanide agent or 4 pharmaceutical agent that enhances the effects of active circulating GLP-2 may be used in combination at the time of administration.
- administration methods may include (1) the administration of a preparation formulated by conjugating a DPPIV inhibitor and either a biguanide agent or a pharmaceutical agent that enhances the effects of active circulating GLP-2; (2) the simultaneous administration of two types of preparations, which are obtained by separately formulating a DPPIV inhibitor and either a biguanide agent or a pharmaceutical agent which enhances the effects of active circulating GLP-2; and (3) the separate administration of two types of preparations, which are obtained by separately formulating a DPPIV inhibitor and either a biguanide agent or a pharmaceutical agent that enhances the effects of active circulating GLP-2 at different times (for example, administering them in the order of the DPPIV inhibitor and then either a biguanide agent or a pharmaceutical agent which enhances the effects of active circulating GLP-2, or in reverse order).
- the dose of the pharmaceutical agents according to the present invention can be selected based on the standard dose of each agent.
- the dose can be appropriately selected based on patient's age, weight, sex, severity of symptoms, dosage form, and disease type.
- the DPPIV inhibitor to be administered orally or parenterally is (S)-1-((3-hydroxy-1-adamantyl)amino)acetyl-2-cyanopyrrolidine or (S)-1-(2-((5-cyanopyridin-2-yl)amino)ethyl-aminoacetyl)-2-cyanopyrrolidine
- the dose can typically be selected from a range of 0.1 to 250 mg/adult/day, preferably 1 to 100 mg/adult/day.
- the dose can typically be selected from a range of 0.01 to 2.0 mg/kg/day, preferably 0.01 to 1.0 mg/kg/day.
- the DPPIV inhibitor is a compound represented by formula (I) or (II), or a salt or hydrate thereof, and it is to be administered orally to an adult, the dose can typically be selected from a range of 0.03 to 1000 mg/day, preferably 0.1 to 500 mg/day, more preferably 0.1 to 100 mg/day.
- the dose can typically be selected from a range of about 1 to 3000 ⁇ g/kg/day, preferably about 3 to 1000 ⁇ g/kg/day.
- the DPPIV inhibitor is to be used in combination with another agent, for example, a biguanide agent, the dose typically ranges from 10 to 2500 mg/adult/day, and preferably ranges from 100 to 1000 mg/adult/day.
- both the DPPIV inhibitor and the biguanide agent can be administered once or several times at the daily dose described above.
- the dose ratio between the respective agents in the pharmaceutical agents according to the present invention can be selected appropriately, based on patient's age, weight, sex, severity of symptoms, dosage form, and disease type.
- the weight:weight dose ratio between the DPPIV inhibitor and the biguanide agent may typically fall within a range of 1:1 to 1:2500, preferably 1:10 to 1:250.
- (S)-1-((3-hydroxy-1-adamantyl)amino)acetyl-indicated herein can be administered at a dose selected from the range of 3 to 1000 ⁇ g/kg.
- a DPPIV inhibitor is used in combination with another agent, for example, a biguanide agent
- the dose typically ranges from 10 to 2500 mg/adult/day, and preferably ranges from 100 to 1000 mg/adult/day.
- reaction solution was concentrated to 50 ml, and washed with 20 ml of t-butyl methyl ether.
- the solution was acidified with concentrated hydrochloric acid.
- the resulting precipitate was collected by filtration, and washed successively with 10 ml of water and 10 ml of t-butyl methyl ether. Thus, 1.03 g of the title compound was obtained.
- reaction mixture was extracted with ethyl acetate-water, and the organic layer was washed with 1N hydrochloric acid, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was triturated with diethyl ether. The crystals were collected by filtration, and washed with diethyl ether. Thus, 3.0 g of the title compound was obtained as a white solid.
- the title compound was obtained by treating [7-(2-butynyl)-1-methyl-2,6-dioxo-1,2,6,7-tetrahydropurin-3-yl]methyl 2,2-dimethylpropionate by the same method as used in Example (1f).
- the title compound was obtained by treating 7-(2-butynyl)-1-methyl-3,7-dihydropurine-2,6-dione by the same method as used in Example (1e).
- This solution was poured into a suspension consisting of 7 g of di-t-butyl dicarbonate, 50 ml of tetrahydrofuran, 100 g of sodium bicarbonate, and 200 ml of water, and the mixture was stirred at room temperature for one hour.
- the reaction mixture was diluted with ethyl acetate, and the mixture was washed with water.
- the organic layer was dried over anhydrous magnesium sulfate, then filtered. The filtrate was concentrated, and the residue was purified by silica gel column chromatography.
- Example (11b) Using ethanol instead of methanol in Example (11b), the trifluoroacetate of the title compound was obtained by the same method as used in Example 11. This compound was purified by chromatography using NH-silica gel. Thus, the title compound was obtained from the fraction eluted with ethyl acetate-methanol (20:1).
- Example 13 Using ethyl 1-hydroxycyclopropanecarboxylate instead of ethyl 2-hydroxyacetate in Example 13, the trifluoroacetate of the title compound was obtained by the same method as used in Example 13. The compound was purified by chromatography using NH-silica gel. Thus, the title compound was obtained from the fraction eluted with ethyl acetate-methanol (20:1).
- Example 13 Using phenol instead of ethyl 2-hydroxyacetate in Example 13, the title compound was obtained by the same method as used in Example 13.
- Example 41 Using L-proline t-butyl ester instead of 2-ethoxyethylamine in Example 41, 4.07 mg of the title compound was obtained by the same method as used in Example 41.
- Example 63 Using DL-alanine methyl ester hydrochloride instead of D-proline methyl ester hydrochloride in Example 63, 1.12 mg of the title compound was obtained by the same method as used in Example 63.
- Example 68 Using 2-mercaptopyridine instead of methyl mercaptoacetate in Example 68, 4.66 mg of the title compound was obtained by the same method as used in Example 68.
- the resulting residue was dissolved in a solution consisting of 0.20 ml of ethanol and 0.20 ml of a 5N aqueous sodium hydroxide solution. The mixture was stirred at room temperature overnight, and then concentrated by flushing with nitrogen gas. The residue was dissolved in 0.40 ml of trifluoroacetic acid, and the solution was concentrated by flushing with nitrogen gas.
- Example 86(e) Using methyl thioglycolate instead of methanol and using potassium carbonate as a base in Example 86(e), the title compound was synthesized by the same method as used in Example 86.
- Example 96(b) Using methanol instead of dimethylamine and using anhydrous potassium carbonate as a base in Example 96(b), the title compound was synthesized by the same method as used in Example 96.
- the mixture was washed with 10 ml of a saturated sodium chloride solution containing 1 ml of 1N sodium hydroxide solution, and dried over anhydrous magnesium sulfate. The solution was filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved in 10 ml of dichloromethane, and 0.10 ml of triethylamine and 0.256 g of di-t-butyl dicarbonate were added thereto. The mixture was stirred at room temperature for 15 hours, and then 25 ml of ethyl acetate was added thereto.
- 0.187 g of mercury (II) acetate and 0.090 of sodium borohydride were added to 8 ml of an ethanol solution containing 0.265 g of t-butyl 4-[1-(2-butynyl)-5-ethoxycarbonyl-4-methylsulfanyl carbonyl-1H-imidazol-2-yl]piperazine-1-carboxylate at 0° C., and the mixture was stirred at room temperature for 4 hours. After 0.187 g of mercury (II) acetate and 0.090 of sodium borohydride had been added to the solution, the mixture was stirred at room temperature for 15 hours.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-280137 | 2002-09-26 | ||
JP2002280137 | 2002-09-26 | ||
JP2003-117927 | 2003-04-23 | ||
JP2003117927 | 2003-04-23 | ||
PCT/JP2003/012075 WO2004028524A1 (fr) | 2002-09-26 | 2003-09-22 | Medicament combine |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060094722A1 true US20060094722A1 (en) | 2006-05-04 |
Family
ID=32044617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/528,353 Abandoned US20060094722A1 (en) | 2002-09-26 | 2003-09-22 | Combination drug |
Country Status (12)
Country | Link |
---|---|
US (1) | US20060094722A1 (fr) |
EP (1) | EP1557165A4 (fr) |
JP (1) | JPWO2004028524A1 (fr) |
KR (1) | KR100867485B1 (fr) |
AU (1) | AU2003266559B2 (fr) |
BR (1) | BR0314655A (fr) |
CA (1) | CA2498423A1 (fr) |
MX (1) | MXPA05003252A (fr) |
NO (1) | NO20052018L (fr) |
NZ (1) | NZ538936A (fr) |
RU (1) | RU2328280C2 (fr) |
WO (1) | WO2004028524A1 (fr) |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040097510A1 (en) * | 2002-08-21 | 2004-05-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20040122228A1 (en) * | 2002-08-22 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040138215A1 (en) * | 2002-11-21 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040138214A1 (en) * | 2002-11-08 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040166125A1 (en) * | 2002-08-22 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
US20050187227A1 (en) * | 2004-02-23 | 2005-08-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition |
US20050203095A1 (en) * | 2004-03-13 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US20050234108A1 (en) * | 2004-02-18 | 2005-10-20 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US20050261352A1 (en) * | 2004-05-10 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
US20060004074A1 (en) * | 2004-06-24 | 2006-01-05 | Boehringer Ingelheim International Gmbh | New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US20060058323A1 (en) * | 2004-09-11 | 2006-03-16 | Boehringer Ingelheim International Gmbh | New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20060063787A1 (en) * | 2002-06-06 | 2006-03-23 | Eisai Co., Ltd. | Condensed imidazole derivatives |
US20060079541A1 (en) * | 2004-09-14 | 2006-04-13 | Boehringer Ingelheim International Gmbh | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20060142310A1 (en) * | 2004-11-05 | 2006-06-29 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines |
US20060247226A1 (en) * | 2001-02-24 | 2006-11-02 | Frank Himmelsbach | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20070027168A1 (en) * | 2005-07-30 | 2007-02-01 | Waldemar Pfrengle | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US20070259900A1 (en) * | 2006-05-04 | 2007-11-08 | Peter Sieger | Polymorphs |
US20080107731A1 (en) * | 2006-05-04 | 2008-05-08 | Anja Kohlrausch | Dpp iv inhibitor formulations |
US20090088569A1 (en) * | 2004-04-10 | 2009-04-02 | Matthias Eckhardt | 2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation, and their use as pharmaceutical compositions |
US7550455B2 (en) | 2003-11-27 | 2009-06-23 | Boehringer Ingelheim International Gmbh | 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition |
US7566707B2 (en) | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20100136127A1 (en) * | 2007-07-19 | 2010-06-03 | Kazumichi Yamamoto | Solid preparation comprising alogliptin and metformin hydrochloride |
US8071583B2 (en) | 2006-08-08 | 2011-12-06 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus |
US8232281B2 (en) | 2006-05-04 | 2012-07-31 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US8846695B2 (en) | 2009-01-07 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
US8853156B2 (en) | 2008-08-06 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US9149478B2 (en) | 2010-06-24 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
US9155705B2 (en) | 2008-04-03 | 2015-10-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9486526B2 (en) | 2008-08-06 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US9526730B2 (en) | 2012-05-14 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9713618B2 (en) | 2012-05-24 | 2017-07-25 | Boehringer Ingelheim International Gmbh | Method for modifying food intake and regulating food preference with a DPP-4 inhibitor |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
US11767321B2 (en) | 2020-10-05 | 2023-09-26 | Enliven Inc. | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1338595B1 (fr) | 2002-02-25 | 2006-05-03 | Eisai Co., Ltd. | Dérivés de Xanthines servant d'inhibiteurs de DPP-IV |
CN100376573C (zh) | 2002-12-04 | 2008-03-26 | 卫材R&D管理有限公司 | 稠合的1,3-二氢-咪唑环化合物 |
JPWO2005051949A1 (ja) * | 2003-11-26 | 2007-06-21 | 住友製薬株式会社 | 新規縮合イミダゾール誘導体 |
WO2005097798A1 (fr) * | 2004-04-10 | 2005-10-20 | Boehringer Ingelheim International Gmbh | Nouvelles 2-amino-imidazo[4,5-d]pyridazin-4-ones et 2-amino-imidazo[4,5-c]pyridin-4-ones, leur production et leur utilisation comme medicaments |
US20070259927A1 (en) * | 2004-08-26 | 2007-11-08 | Takeda Pharmaceutical Company Limited | Remedy for Diabetes |
EP1841448A2 (fr) | 2004-12-30 | 2007-10-10 | Diakine Therapeutics, Inc. | Compositions pharmaceutiques et procedes pour le retablissement de masse et de fonction de cellule-beta |
WO2006086727A2 (fr) * | 2005-02-09 | 2006-08-17 | Entelos, Inc. | Traitement des diabetes au moyen de secretagogues du glucagon-like peptide 1 |
ME02005B (fr) | 2005-09-14 | 2012-08-31 | Takeda Pharmaceuticals Co | Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete |
CA2622642C (fr) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Inhibiteurs de dipeptidylpeptidase |
CA2633167A1 (fr) | 2005-12-16 | 2007-07-12 | Merck & Co., Inc. | Compositions pharmaceutiques contenant des combinaisons d'inhibiteurs de la dipeptidylpeptidase 4 avec de la metformine |
WO2007112347A1 (fr) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la dipeptidyl peptidase |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
WO2008130314A1 (fr) * | 2007-04-18 | 2008-10-30 | Astrazeneca Ab | Composés de xanthine ayant un effet modulateur allostérique positif du récepteur gaba b |
CN111036392B (zh) * | 2019-12-04 | 2022-03-08 | 北京矿冶科技集团有限公司 | 一种微细粒铜铅混合精矿的组合抑制剂和分离方法 |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
US6242422B1 (en) * | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
US6716842B2 (en) * | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
US20040082570A1 (en) * | 2002-02-25 | 2004-04-29 | Eisai Co., Ltd. | Xanthine derivative and DPPIV inhibitor |
US20040116328A1 (en) * | 2002-06-06 | 2004-06-17 | Eisai Co., Ltd. | Condensed imidazole derivatives |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9823885D0 (en) * | 1998-10-30 | 1998-12-30 | Aquacal Limited | Foodstuff compositions |
PT1248604E (pt) * | 2000-01-21 | 2007-01-31 | Novartis Ag | Associações compreendendo inibidor de dipeptidilpeptidase-iv |
GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
AU2001268958B2 (en) * | 2000-07-04 | 2006-03-09 | Novo Nordisk A/S | Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv |
SK288003B6 (sk) * | 2001-02-24 | 2012-10-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthin derivatives, method for the preparation thereof, pharmaceutical composition containing thereof and their use |
WO2003004496A1 (fr) * | 2001-07-03 | 2003-01-16 | Novo Nordisk A/S | Derives de purine inhibiteurs de dpp-iv pour le traitement du diabete |
-
2003
- 2003-09-22 AU AU2003266559A patent/AU2003266559B2/en not_active Ceased
- 2003-09-22 MX MXPA05003252A patent/MXPA05003252A/es unknown
- 2003-09-22 JP JP2004539479A patent/JPWO2004028524A1/ja active Pending
- 2003-09-22 CA CA002498423A patent/CA2498423A1/fr not_active Withdrawn
- 2003-09-22 EP EP03798438A patent/EP1557165A4/fr not_active Withdrawn
- 2003-09-22 NZ NZ538936A patent/NZ538936A/en unknown
- 2003-09-22 RU RU2005112447/15A patent/RU2328280C2/ru active
- 2003-09-22 KR KR1020057005167A patent/KR100867485B1/ko not_active IP Right Cessation
- 2003-09-22 WO PCT/JP2003/012075 patent/WO2004028524A1/fr active Application Filing
- 2003-09-22 BR BR0314655-3A patent/BR0314655A/pt not_active IP Right Cessation
- 2003-09-22 US US10/528,353 patent/US20060094722A1/en not_active Abandoned
-
2005
- 2005-04-25 NO NO20052018A patent/NO20052018L/no unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
US6242422B1 (en) * | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
US20040082570A1 (en) * | 2002-02-25 | 2004-04-29 | Eisai Co., Ltd. | Xanthine derivative and DPPIV inhibitor |
US6716842B2 (en) * | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
US20040116328A1 (en) * | 2002-06-06 | 2004-06-17 | Eisai Co., Ltd. | Condensed imidazole derivatives |
Cited By (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060247226A1 (en) * | 2001-02-24 | 2006-11-02 | Frank Himmelsbach | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20100173916A1 (en) * | 2001-02-24 | 2010-07-08 | Boehringer Ingelheim International Gmbh | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions |
US20100204250A1 (en) * | 2001-02-24 | 2010-08-12 | Boehringer Ingelheim Pharma & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7772226B2 (en) | 2002-06-06 | 2010-08-10 | Eisai R&D Management Co., Ltd. | Condensed imidazole derivatives |
US20090018331A1 (en) * | 2002-06-06 | 2009-01-15 | Eisai R&D Management Co., Ltd. | Condensed imidazole derivatives |
US20060100199A1 (en) * | 2002-06-06 | 2006-05-11 | Seiji Yoshikawa | Novel condensed imidazole derivatives |
US20060063787A1 (en) * | 2002-06-06 | 2006-03-23 | Eisai Co., Ltd. | Condensed imidazole derivatives |
US9556175B2 (en) | 2002-08-21 | 2017-01-31 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions |
US8178541B2 (en) | 2002-08-21 | 2012-05-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8664232B2 (en) | 2002-08-21 | 2014-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US10202383B2 (en) | 2002-08-21 | 2019-02-12 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20040097510A1 (en) * | 2002-08-21 | 2004-05-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US10023574B2 (en) | 2002-08-21 | 2018-07-17 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20080255159A1 (en) * | 2002-08-21 | 2008-10-16 | Boehringer Ingelheim Pharma Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8119648B2 (en) | 2002-08-21 | 2012-02-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9321791B2 (en) | 2002-08-21 | 2016-04-26 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US9108964B2 (en) | 2002-08-21 | 2015-08-18 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7495005B2 (en) | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
US7569574B2 (en) * | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7838529B2 (en) | 2002-08-22 | 2010-11-23 | Boehringer Ingelheim International Gmbh | Xanthine derivates, their preparation and their use in pharmaceutical compositions |
US20090131432A1 (en) * | 2002-08-22 | 2009-05-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivates, their preparation and their use in pharmaceutical compositions |
US20040122228A1 (en) * | 2002-08-22 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040166125A1 (en) * | 2002-08-22 | 2004-08-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
US7696212B2 (en) | 2002-11-08 | 2010-04-13 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040138214A1 (en) * | 2002-11-08 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20100144703A1 (en) * | 2002-11-08 | 2010-06-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20040138215A1 (en) * | 2002-11-21 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7560450B2 (en) | 2002-11-21 | 2009-07-14 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7566707B2 (en) | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US20090258856A1 (en) * | 2003-06-18 | 2009-10-15 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US8034941B2 (en) | 2003-06-18 | 2011-10-11 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7550455B2 (en) | 2003-11-27 | 2009-06-23 | Boehringer Ingelheim International Gmbh | 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition |
US20090137801A1 (en) * | 2004-02-18 | 2009-05-28 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US8697868B2 (en) | 2004-02-18 | 2014-04-15 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US20050234108A1 (en) * | 2004-02-18 | 2005-10-20 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
US20050187227A1 (en) * | 2004-02-23 | 2005-08-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition |
US7645763B2 (en) | 2004-02-23 | 2010-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical composition |
US20050203095A1 (en) * | 2004-03-13 | 2005-09-15 | Boehringer Ingelheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US7432262B2 (en) | 2004-03-13 | 2008-10-07 | Boehringer Ingelheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US7393847B2 (en) | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US20090088569A1 (en) * | 2004-04-10 | 2009-04-02 | Matthias Eckhardt | 2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation, and their use as pharmaceutical compositions |
US20050261352A1 (en) * | 2004-05-10 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
US7667035B2 (en) | 2004-05-10 | 2010-02-23 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
US7439370B2 (en) | 2004-05-10 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
US20060004074A1 (en) * | 2004-06-24 | 2006-01-05 | Boehringer Ingelheim International Gmbh | New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US7906539B2 (en) | 2004-06-24 | 2011-03-15 | Boehringer Ingelheim International Gmbh | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US20080312243A1 (en) * | 2004-06-24 | 2008-12-18 | Matthias Eckhardt | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US7470716B2 (en) | 2004-06-24 | 2008-12-30 | Boehringer Ingelheim International Gmbh | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions |
US7495003B2 (en) | 2004-09-11 | 2009-02-24 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20060058323A1 (en) * | 2004-09-11 | 2006-03-16 | Boehringer Ingelheim International Gmbh | New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7495002B2 (en) | 2004-09-14 | 2009-02-24 | Boehringer Ingelheim International Gmbh | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US20060079541A1 (en) * | 2004-09-14 | 2006-04-13 | Boehringer Ingelheim International Gmbh | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7820815B2 (en) | 2004-11-05 | 2010-10-26 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines |
US9499546B2 (en) | 2004-11-05 | 2016-11-22 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US8883805B2 (en) | 2004-11-05 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US20090192314A1 (en) * | 2004-11-05 | 2009-07-30 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines |
US20060142310A1 (en) * | 2004-11-05 | 2006-06-29 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines |
US9751855B2 (en) | 2004-11-05 | 2017-09-05 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
US8541450B2 (en) | 2004-11-05 | 2013-09-24 | Boehringer Ingelheim International Gmbh | Process for the preparation of chiral 8-(3-aminopiperidin-1yl)-xanthines |
US8106060B2 (en) | 2005-07-30 | 2012-01-31 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US8637530B2 (en) | 2005-07-30 | 2014-01-28 | Boehringer Ingelheim International Gmbh | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US20070027168A1 (en) * | 2005-07-30 | 2007-02-01 | Waldemar Pfrengle | 8-(3-amino-piperidin-1-yl)-xanthines, their preparation, and their use as pharmaceuticals |
US11084819B2 (en) | 2006-05-04 | 2021-08-10 | Boehringer Ingelheim International Gmbh | Polymorphs |
US10080754B2 (en) | 2006-05-04 | 2018-09-25 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US11033552B2 (en) | 2006-05-04 | 2021-06-15 | Boehringer Ingelheim International Gmbh | DPP IV inhibitor formulations |
US11291668B2 (en) | 2006-05-04 | 2022-04-05 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US10301313B2 (en) | 2006-05-04 | 2019-05-28 | Boehringer Ingelheim International Gmbh | Polymorphs |
US9493462B2 (en) | 2006-05-04 | 2016-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
US20080107731A1 (en) * | 2006-05-04 | 2008-05-08 | Anja Kohlrausch | Dpp iv inhibitor formulations |
US9266888B2 (en) | 2006-05-04 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Polymorphs |
US20070259900A1 (en) * | 2006-05-04 | 2007-11-08 | Peter Sieger | Polymorphs |
US8232281B2 (en) | 2006-05-04 | 2012-07-31 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
US8673927B2 (en) | 2006-05-04 | 2014-03-18 | Boehringer Ingelheim International Gmbh | Uses of DPP-IV inhibitors |
US9173859B2 (en) | 2006-05-04 | 2015-11-03 | Boehringer Ingelheim International Gmbh | Uses of DPP IV inhibitors |
US9815837B2 (en) | 2006-05-04 | 2017-11-14 | Boehringer Ingelheim International Gmbh | Polymorphs |
US11919903B2 (en) | 2006-05-04 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Polymorphs |
US8071583B2 (en) | 2006-08-08 | 2011-12-06 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus |
US8900638B2 (en) | 2007-07-19 | 2014-12-02 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
US20100136127A1 (en) * | 2007-07-19 | 2010-06-03 | Kazumichi Yamamoto | Solid preparation comprising alogliptin and metformin hydrochloride |
US20110014299A2 (en) * | 2007-07-19 | 2011-01-20 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
US10022379B2 (en) | 2008-04-03 | 2018-07-17 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9155705B2 (en) | 2008-04-03 | 2015-10-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US10973827B2 (en) | 2008-04-03 | 2021-04-13 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US9415016B2 (en) | 2008-04-03 | 2016-08-16 | Boehringer Ingelheim International Gmbh | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
US10034877B2 (en) | 2008-08-06 | 2018-07-31 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US9486526B2 (en) | 2008-08-06 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US8853156B2 (en) | 2008-08-06 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients inappropriate for metformin therapy |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US11911388B2 (en) | 2008-10-16 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
US9212183B2 (en) | 2008-12-23 | 2015-12-15 | Boehringer Ingelheim International Gmbh | Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
US8846695B2 (en) | 2009-01-07 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
US10092571B2 (en) | 2009-11-27 | 2018-10-09 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US9457029B2 (en) | 2009-11-27 | 2016-10-04 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
US10004747B2 (en) | 2010-05-05 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9603851B2 (en) | 2010-05-05 | 2017-03-28 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
US9149478B2 (en) | 2010-06-24 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US11911387B2 (en) | 2010-11-15 | 2024-02-27 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US8962636B2 (en) | 2011-07-15 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9199998B2 (en) | 2011-07-15 | 2015-12-01 | Boehringer Ingelheim Internatioal Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US10195203B2 (en) | 2012-05-14 | 2019-02-05 | Boehringr Ingelheim International GmbH | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9526730B2 (en) | 2012-05-14 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
US9713618B2 (en) | 2012-05-24 | 2017-07-25 | Boehringer Ingelheim International Gmbh | Method for modifying food intake and regulating food preference with a DPP-4 inhibitor |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
US11807638B2 (en) | 2020-10-05 | 2023-11-07 | Enliven Inc. | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases |
US11767321B2 (en) | 2020-10-05 | 2023-09-26 | Enliven Inc. | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases |
Also Published As
Publication number | Publication date |
---|---|
NZ538936A (en) | 2006-12-22 |
MXPA05003252A (es) | 2005-07-05 |
JPWO2004028524A1 (ja) | 2006-01-19 |
AU2003266559B2 (en) | 2008-01-24 |
NO20052018L (no) | 2005-06-22 |
RU2005112447A (ru) | 2006-01-20 |
EP1557165A4 (fr) | 2008-12-03 |
EP1557165A1 (fr) | 2005-07-27 |
KR100867485B1 (ko) | 2008-11-10 |
RU2328280C2 (ru) | 2008-07-10 |
BR0314655A (pt) | 2005-08-02 |
AU2003266559A2 (en) | 2005-07-07 |
KR20050074460A (ko) | 2005-07-18 |
WO2004028524A1 (fr) | 2004-04-08 |
AU2003266559A1 (en) | 2004-04-19 |
CA2498423A1 (fr) | 2004-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060094722A1 (en) | Combination drug | |
US20070219178A1 (en) | Preventive or therapeutic agents for multiple sclerosis | |
US7772226B2 (en) | Condensed imidazole derivatives | |
US9006177B2 (en) | Fused tricyclic compounds as adenosine receptor antagonist | |
EP1338595A2 (fr) | Dérivés de Xanthines servant d'inhibiteurs de DPP-IV | |
US20090247539A1 (en) | Novel Pharmaceuticals | |
JP2004043429A (ja) | 新規キサンチン誘導体およびdppiv阻害剤 | |
EP2125803A1 (fr) | Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations | |
WO1999043678A1 (fr) | Medicaments et prophylaxie contre la maladie de parkinson | |
US11981679B2 (en) | Tricyclic compounds, compositions and medicinal applications thereof | |
EP2619211B1 (fr) | Composés tricycliques fusionnés utilisés comme antagonistes du récepteur de l'adénosine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: EISAI CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YASUDA, NOBUYUKI;YAMAZAKI, KAZUTO;REEL/FRAME:016964/0365 Effective date: 20050509 |
|
AS | Assignment |
Owner name: EISAI R&D MANAGEMENT CO., LTD., JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EISAI CO., LTD.;REEL/FRAME:019265/0447 Effective date: 20070419 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |